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Abstract
Purpose: This study examined the influence of genotype polymorphisms (specifically
ACTN3 R577X, IGF-II C13790C, IGF-II G17200A, IGF2AS A1364C, IGF2AS
G11711T) on markers of skeletal muscle recovery following an acute bout of heavy
endurance exercise, and assessed their role in determining individual responses to
carbohydrate-protein supplementation. Methods: Twelve trained male cyclists completed
repeated cycling trials, each consisting of an initial session of glycogen-depleting
exercise, followed four hours later by a >1 hr time-trial on a computerized cycle
ergometer (VeloTron, Racermate, Inc). Subjects were randomly administered a highcarbohydrate low-protein (HCLP), or carbohydrate-only (CHO) beverage, which was
consumed immediately and 2-hours post glycogen depleting exercise, and immediately
following subsequent exercise. Beverages were isocaloric and isovolumetric. Blood
samples were obtained before the glycogen-depleting exercise of the first trial for
genotyping analysis. Serum creatine kinase (CK), peak muscle function (MVC), mental
and physical energy and fatigue ratings, and muscle soreness ratings were obtained as
markers of muscle recovery at specific time points. Subjects completed these methods for
both treatments in a double-blind protocol. Results: Changes in MVC were significantly
different (P < 0.05) from baseline to 4-hours post glycogen depleting exercise among
genotypes for the ACTN3 R577X, IGF-II C13790C, and IGF2AS A1364C single
nucleotide polymorphisms (SNPs) during the CHO control trial. Changes in
mental/physical energy/fatigue and muscle soreness ratings were significantly different
(P < 0.05) from baseline to 24-hours post glycogen depleting exercise among genotypes
for the ACTN3 R577X and IGF2AS G11711C SNPs during the CHO control trial. These

vii

variables tended to improve with the HCLP treatment when subjects identified for the
above genotype variations were analyzed, although the improvements were not
statistically significant. Changes in serum CK were not significantly different (P > 0.05)
from baseline to 4-hours post glycogen depleting exercise among genotypes analyzed.
Conclusions: Genotype variations led to significant differences in MVC, physical/mental
energy/fatigue and muscle soreness ratings, which tended to improve with the HCLP
treatment. There were no genotype effects for serum CK.
Key Words: Genotype, Carbohydrate, Protein, Muscle Damage, Recovery
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Chapter I
Introduction

This study shall attempt to analyze the roles of genotypes on the extent of muscle
damage, and the subsequent rate of muscle recovery, following intense aerobic exercise.
The findings should enhance understanding of the variations in response to post-exercise
recovery beverages with protein among endurance-trained individuals.

Background
Prolonged high-intensity endurance exercise is associated with depleted glycogen
stores and impairments in markers of muscle recovery. Traditionally, sports beverages
containing water, carbohydrate, and electrolytes have been utilized by endurance athletes
to enhance glycogen replenishment, facilitate muscle recovery, and improve aerobic
performance (Hargreaves et al., 1984; Coyle and Coggan, 1984; Coggan and Coyle 1991;
Coyle, 1992; 1992; Halson, 2004). Recently, the inclusion of protein into carbohydratebased sport beverages to confer additional performance benefits has garnered
considerable attention in the field of exercise science. The inclusion of protein content is
proposed to enhance the rate of muscle recovery, as well as improve subsequent
endurance performance (Saunders et al., 2004; Betts et al., 2007; Berardi et al., 2008;
Rowland et al., 2008; and Skillen et al., 2008).
Current studies examining the efficacy of carbohydrate-protein supplementations
have demonstrated mixed results. Some studies have documented improved performance
in subsequent exercise bouts (Saunders et al., 2004; Betts et al., 2007; Berardi et al.,
2008; Rowland et al., 2008; and Skillen et al., 2008), as well as reductions in markers of
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muscle damage and soreness (Saunders et al., 2004; Millard-Stafford et al., 2005;
Romano-Ely et al., 2006; Rowland et al., 2008; and Skillen et al., 2008) with
carbohydrate-protein ingestion. However, other studies have reported no differences in
subsequent exercise performances between carbohydrate and carbohydrate-protein
beverages (Millard-Stafford et al., 2005; Romano-Ely et al., 2006; Betts et al., 2007). In
addition to the variations between studies, there appears to be considerable variations
among individual subjects with respect to the potential efficacy of carbohydrate-protein
ingestion. For example, Combest et al. (2005) reported that 10 of 14 cyclists performing
exhaustive exercise observed sizable attenuations in post-exercise serum CK levels (ΔCK
= 975 ± 590 U/L) with carbohydrate-protein ingestion, while the remaining four subjects
were non-responders (ΔCK = -10.0 ± 31.6 U/L) to carbohydrate-protein intake.
Furthermore, the carbohydrate-protein „responders‟ experienced improvements in
subsequent exercise performance that were significantly greater than those who were
„non-responders‟.
The variations in findings within current literature suggest that some individuals
are better responders to carbohydrate-protein supplementation than others, although the
mechanism for the variations remains unclear. One possible explanation may lie in the
role of specific genetic polymorphisms. Certain genotypes may predispose individuals to
greater muscle damage following exercise. Hence, such individuals would potentially
respond better to sports recovery beverages containing protein.

Rationale
Current studies examining genotype associations with muscle damage have
identified specific genotypes associated with increased skeletal muscle damage following
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acute exercise: MLCK C37885A (Clarkson et al., 2005), IGF-II C13790G, IGF-II
G17200A, IGF2AS A1364C, IGF2AS G11711T (Devaney et al., 2007), and ACE ID
(Yamin et al., 2007). However, these studies have primarily incorporated eccentric
resistance exercise protocols. The association between genotypes and aerobic exerciseinduced muscle damage is therefore not well understood.
Hence, the present study seeks to determine if genetic polymorphisms influence
muscle damage/recovery variables following heavy endurance exercise. This would
address and account for the wide variations in responses to performance recovery
beverages containing protein following intense aerobic exercise.

Purpose
This study seeks to evaluate the influence of genetic polymorphisms (specifically
IGF-II C13790G, IGF-II G17200A, IGF2AS A1364C, IGF2AS G11711T, and ACTN3
R577X) on the rate of muscle recovery, as measured by serum creatine kinase (CK)
levels, peak muscle function (MVC), perceived muscle soreness, and ratings of
energy/fatigue following heavy endurance exercise. The findings may help to determine
the likelihood of individuals responding to recovery beverages containing protein.

Hypotheses
1) The variations between genotypes among subjects will lead to significant differences
in the following muscle damage variables after acute heavy endurance exercise:
serum CK levels, peak muscle function (MVC), perceived physical and mental
energy and fatigue levels, and perceived muscle soreness levels.
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2) Subjects with genotypes that are associated with greater increases in the above muscle
damage variables will derive significant reductions in these variables, and significant
improvements in time to completion during a subsequent endurance performance
exercise with the ingestion of high carbohydrate – low protein beverages.

Assumptions
1) Subjects participated in a maximal cycle test before the start of the study to determine

their VO2peak and maximal power. The oxygen uptake measurement served as an
exclusion criterion, while the power score was used to determine workload performed
during the glycogen depleting exercise, and the steady state portion of the subsequent
exercise. Therefore, it was assumed that all subjects provided a maximal effort during
this test.
2) Subjects completed a maximum voluntary isometric contraction of the quadriceps to

assess peak muscle function on five separate occasions for each trial. It was assumed
that subjects gave a maximal effort during each of these occasions.
3) It was assumed that subjects adhered to instructions to consume no other calories

other than their standardized breakfast 12-hours prior to each training session. It was
also assumed that subjects did not consume any calories besides the treatment
provided during the 4-hour recovery period between the glycogen depleting exercise
and the subsequent time-trial. It was finally assumed that subjects did not consume
any calories besides the treatment provided for two hours after the subsequent time
trial.
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4) Subjects were instructed to treat each subsequent time-trial as a competitive race, and

provide a maximal effort. It was therefore assumed that subjects provided a maximal
effort during their subsequent performance rides.

Definition of Terms
1) Genotype: genetic constitution of an organism, determined by the allele composition.
2) Allele: Variations in DNA sequence in a chromosome (DNA and protein structure
found in cells).
- Heterozygous: possessing 2 different variants of an allele.
- Homozygous: possessing identical alleles.
3) Polymorphism: Common variations of DNA resulting from mutations.
4) Single Nucleotide Polymorphism (SNP): Variation in DNA sequence between
individuals involving a single nucleotide– A, G, C, T (nucleotides are molecules that
form the structure of DNA.

Chapter II
Review of Literature
Carbohydrate-based sports beverages have been demonstrated to improve athletic
performance during heavy endurance exercise. The addition of protein into carbohydratebased sport beverages to confer additional performance benefits in aerobic exercise has
been recently investigated within the last decade. Current literature is inconclusive on the
effectiveness of carbohydrate-protein supplementation as performance enhancement
beverages for acute endurance exercise (Table 2.1). Some studies have demonstrated
enhanced cycling time trial performance and time to fatigue with carbohydrate-protein
ingestion. Conversely, other studies reported a lack of substantial improvements in time
to exhaustion and time to completion when protein calories were added into carbohydrate
beverages.
When utilized as a performance recovery beverage, current literature is more
positive on the effectiveness of carbohydrate-protein supplementation in subsequent
endurance performance (Table 2.2), as evidenced by improvements in subsequent time
trial performances and times to exhaustion. Studies examining physiological recovery
variables have reported attenuated plasma CK levels, and reduced levels of perceived
muscle soreness following heavy endurance exercise with carbohydrate-protein
supplementation. Despite these documented benefits, there are variations between studies
in the magnitude and extensiveness of the benefits among subjects. One possible
explanation for the variability in recovery benefits with carbohydrate-protein
supplementation, as well as the variations in findings on acute endurance exercise, may
be the role of genotypes.
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Genotyping studies have revealed that genetic variations may account for
differences in sport performance (Table 2.3), muscle function (Table 2.4), and skeletal
muscle damage accrued following exercise (Table 2.5). In sports performance, the
ACTN3 R allele and RR genotype are associated with enhanced sprint performance,
whereas the ACTN3 X allele and XX genotype are associated with augmented endurance
performance. For muscle function, the ACE D allele and ACE DD genotype are
associated with increased type II fiber distribution, and improved muscular strength,
whereas the ACE I allele and ACE II genotype are associated with increased type I fiber
distribution. In terms of skeletal muscle damage, MLCK C37885A, IGF II G/C, IGF2AS
A1364C, IGF2AS G11711T, and ACE II allele have been identified with increased CK
levels and/or strength loss following resistance exercise protocols.
The present study aims to examine the influence of genotypes on the rate of
muscle recovery following heavy endurance exercise, which may help determine
individual responses to recovery beverages containing protein.
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Table 2.1: Carbohydrate and Protein and Acute Endurance Performance.
Articles
Effect of a
carbohydrateprotein
supplement on
endurance
performance
during exercise
of varying
intensity (Ivy et
al., 2003)

Effects of a
carbohydrateprotein beverage
on cycling
endurance and
muscle damage
(Saunders, Kane,
and Todd, 2004)

Problem/Question
studied
To compare the
effects of a
carbohydrate
protein supplement
against a
carbohydrate-only
supplement, and a
sweetened placebo,
on aerobic
endurance
performance.

Participants

Procedures

Findings

9 trained male
cyclists (27.3 +
1.3 yr, 69.6 +
2.5 kg, 52.6 +
10.3 ml/kg/min)

Subjects performed three
trials of cycle ergometry
at 45 – 75% of VO2max
for 3 hr, and then at 85%
VO2max to exhaustion.
During each separate
trial, subjects were
administered 200 ml of
the sweetened placebo, a
7.75% liquid
carbohydrate supplement,
or a 7.75%/1.94% protein
supplement immediately
prior to the start of
exercise, and every 20
minutes during exercise,
until 85% VO2max was
achieved. Subsequent
trials were performed 7 –
14 days apart with the
alternate treatment
beverages.

To compare the
effects of a
carbohydrateprotein beverage
against a
carbohydrate-only
beverage on
cycling endurance
performance and
post-exercise
muscle damage.

15 trained male
cyclists (20.9 +
3.3 yr, 73.3 +
6.4 kg, 52.6 +
10.3 ml/kg/min)

Subjects performed two
trials of cycle ergometry
to exhaustion (at 75%
and 85% VO2peak
respectively, 12 – 15 hr
apart). Subjects were
administered 1.8 ml/kg
bodyweight of randomly
assigned carbohydrate or
carbohydrate-protein
beverage every 15
minute during exercise,
and 10 ml/kg bodyweight
of the same treatment
post-exercise. The
protocol was repeated 7 –
14 days later with the
other treatment beverage.

The time to exhaustion
was significantly longer
with consumption of the
carbohydrate-only
supplement, when
compared to the placebo.
The time to exhaustion
was significantly longer
with consumption of the
carbohydrate-protein
supplement, when
compared to the
carbohydrate-only
supplement. Measured
physiological variables
(respiratory exchange
ratio, blood glucose,
plasma insulin, plasma
free fatty acid, and blood
lactate) did not differ
significantly between the
carbohydrate-only and
carbohydrate protein
treatments. These findings
suggest that the addition
of protein content to a
carbohydrate supplement
improves aerobic
endurance performance
above that of a
carbohydrate-only
supplement, although the
mechanism behind this
benefit is not completely
understood.
The time to exhaustion
was significantly longer in
the initial performance
ride with consumption of
the carbohydrate-protein
beverage, when compared
to the carbohydrate-only
beverage (P < 0.05). This
finding demonstrates a
significant improvement
in acute cycling times to
exhaustion with the
addition of protein
calories in carbohydrate
beverages.
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Failure of
protein to
improve time
trial
performance
when added to a
sports drink
(Van Essen and
Gibala, 2006)

To compare the
effects of adding
2% protein to a 6%
carbohydrate
beverage on 80 km
cycling time trial
performances
against a 6%
carbohydrate drink
and a nonenergetic
sweetened placebo.

10 trained male
cyclists (24 + 2
yr, 76 + 2 kg, 63
+ 2 ml/kg/min)

Subjects performed three
separate 80 km time trials
on the cycle ergometer.
During each separate
trial, subjects were
administered 250 ml of
the carbohydrate-protein,
carbohydrate, or placebo
beverage every 15
minutes during exercise.
Subsequent trials were
performed 7 days apart
with the alternate
treatment beverages.

Effects of an
isocaloric
carbohydrateproteinantioxidant drink
on cycling
performance
(Romano-Ely et
al., 2006)

To compare the
effects of a
carbohydrateprotein-antioxidant
beverage against a
carbohydrate-only
beverage on
cycling endurance
performance and
post-exercise
muscle damage.

14 trained male
cyclists (24.0 +
4.1 yr, 59.8 +
11.9 ml/kg/min)

Subjects performed two
trials of cycle ergometry
to exhaustion (at 70%
and 80% VO2peak
respectively, 24 hr apart).
Subjects were
administered 2.0 ml/kg
bodyweight of randomly
assigned carbohydrateprotein-antioxidant of
carbohydrate-only
beverage every 15
minutes during exercise,
and 10 ml/kg bodyweight
of the same treatment
post-exercise. The
protocol was repeated 1 –
2 weeks later with the
alternate treatment
beverage.

The times to completion
were significantly faster
with consumption of the
carbohydrate-protein and
carbohydrate beverages,
than with consumption of
the placebo (P < 0.002).
There were no significant
differences in time to
completion between the
carbohydrate-protein and
carbohydrate beverages (P
= 0.92). These findings
suggest that while the
carbohydrate-protein
beverage improved 80 km
cycle time trial
performances, additional
protein content does not
appear to confer further
benefits in improving the
time to completion.
The times to fatigue were
not significantly different
between the two treatment
beverages in the initial
70% VO2peak trial (P =
0.77), and in the
subsequent 80% VO2peak
trial (P = 0.91). Postexercise CK levels (P <
0.05) and 24 hr CK levels
(P < 0.05) were
significantly higher with
carbohydrate ingestion
than carbohydrate-proteinantioxidant ingestion.
Post-exercise LDH levels
(P < 0.05) and 24 hr LDH
levels (P < 0.05) were
significantly higher with
carbohydrate ingestion
than carbohydrate-proteinantioxidant ingestion.
Peak muscle soreness
levels 24 hr post-exercise
were significantly higher
with carbohydrate
ingestion than
carbohydrate-proteinantioxidant ingestion (P <
0.05). These findings
demonstrate that the
carbohydrate-proteinantioxidant beverage
significantly attenuated
post-exercise muscle
damage and subjective
muscle soreness, but the
additional protein content
did not improve time to
exhaustion significantly.
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Consumption of
an oral
carbohydrateprotein gel
improves
cycling
endurance and
prevents postexercise muscle
damage
(Saunders,
Luden, and
Herrick, 2007)

To compare the
effects of an oralcarbohydrateprotein gel against
a carbohydrate
only gel on cycling
endurance
performance and
post-exercise
muscle damage,
and to compare
responses between
genders.

13 trained
cyclists: 8 males
(23.8 + 7.4 yr,
74.8 + 10.1 kg,
61.5 + 4.2
ml/kg/min), 5
females (24.8 +
6.4 yr, 61.1 +
7.0 kg, 51.3 +
4.9 ml/kg/min)

Subjects performed two
bouts of cycle ergometry
to exhaustion at 75%
VO2peak. Subjects were
randomly administered
carbohydrate-protein or
carbohydrate only gels
every 15 minutes during
exercise, and the same
treatment with water
immediately postexercise. The protocol
was repeated 7 – 14 days
later with the alternate
treatment beverage.

Influence of
carbohydrateprotein beverage
on cycling
endurance and
indices of
muscle
disruption
(Valentine et al.,
2008)

To examine the
effects of
carbohydrateprotein beverage
ingestion on time
to exhaustion and
markers of muscle
disruption
compared to
placebo and
carbohydrate
beverages matched
for carbohydrate
(CHO) and total
calories

11 trained male
cyclists (20.8 +
2.4 yr, 75.2 +
11.6 kg, 53.4+
7.2 ml/kg/min)

Subjects performed four
separate cycle ergometry
rides to exhaustion at
75% VO2peak, at a
cadence of 50 rpm.
Subjects were randomly
administered 250 ml of a
placebo, a carbohydrate
only (6%) beverage, a
higher dosage (9.69%) of
carbohydrate beverage,
or a carbohydrate
(7.75%) and protein
(1.94%) beverage every
15 min until fatigue.
Subsequent trials were
performed 5-7 days apart
with the alternate
treatment beverages.

The time to exhaustion
was significantly longer
with ingestion of the
carbohydrate-protein gel,
than the carbohydrate-only
gel (P < 0.05). There were
no gender differences in
time to exhaustion (P =
0.98). The increase in CK
levels post-exercise was
significantly lower with
ingestion of the
carbohydrate-protein gel
(P < 0.05). These findings
suggest that ingestion of a
carbohydrate-protein gel
during and after exercise
improves cycling
endurance performance,
and attenuates muscle
damage.
The cycling times to
exhaustion were
significantly longer with
the carbohydrate-protein
and the higher dosage of
carbohydrate beverages,
than the placebo (P <
0.05). There were no
significant differences in
times to exhaustion
between the lower dosage
carbohydrate beverage and
the placebo, or between
the carbohydrate-protein
beverage, the higher
dosage of carbohydrate
beverage, and the lower
dosage of carbohydrate
beverage. Post-exercise
plasma creatine kinase and
serum myoglobin were
lower during the
carbohydrate-protein trial
than all the other
treatments. The number of
24hr post-exercise leg
extensions performed at
70% of 1 RM was
significantly greater in the
carbohydrate protein trial
than all other treatments.
These findings suggest
caloric differences may
account for improved
endurance performance
with carbohydrate-protein
beverages, whereas
improvements in muscle
recovery variables are
independent of caloric
content and carbohydrate.
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Carbohydrate &
carbohydrate +
protein for
cycling timetrial
performance
(Osterberg,
Zachwieja, and
Smith, 2008)

To determine if
carbohydrateprotein ingestion
significantly
improves cycling
time-trial
performance
relative to placebo
and carbohydrate

13 trained male
cyclists (31.2 +
2.4 yr, 73.4 +
9.0 kg, 56.0 +
6.9 ml/kg/min)

Subjects performed three
separate experimental
trials of constant-load
cycle ergometry for 120
min, followed
immediately by a timetrial in which they
completed a set amount
of work as quickly as
possible (7 kJ/kg).
Subjects were randomly
administered 250 ml of a
placebo, a carbohydrate
only (6%) beverage, or a
carbohydrate (7.5%) and
protein (1.6%) beverage
every 15 min during the
constant-load ride.
Subsequent trials were
performed 5-7 days apart
with the alternate
treatment beverages.

Carbohydrate
and protein
hydrolysate coingestion
improves lateexercise timetrial
performance
(Saunders et al.,
2009)

To compare the
effects of a
carbohydratecasein hydrolysate
beverage against a
carbohydrate only
beverage on
cycling time trial
performance, and
markers of muscle
disruption and
recovery.

13 trained male
cyclists (25.3 +
2.4 yr, 73.0 +
2.6 kg, 60.8 +
1.6 ml/kg/min)

Subjects performed two
simulated 60 km cycle
time trials with a 5%
grade in the last 5 km.
Subjects were
administered 200 ml
randomly assigned
carbohydrate-only
beverage (6%) or
carbohydrate-casein
hydrolysate beverage
(6% + 1.8%) every 5 km
during exercise, and 500
ml of the same treatment
immediately postexercise. The protocol
was repeated 7 – 10 days
later with the alternate
treatment beverage.

The time trial performance
was significantly faster (P
< 0.05), and the power
output during the time trial
was significantly higher (P
< 0.05) with ingestion of
the carbohydrate-only
beverage, compared to the
placebo. The time trial
performance and power
output during the time trial
were not significantly
different with ingestion of
the carbohydrate-protein
beverage, than either the
carbohydrate-only or
placebo beverage. The
RPE, heart rate, and
percent hydration during
the constant-load ride
were not different between
all three treatments. These
findings suggest that the
carbohydrate-protein
beverage provide no
additional benefit to cycle
time-trial performance.
The riding times in the
final 20 km of the time
trials and the last 5 km
with 5% grade were
significantly faster with
ingestion of the
carbohydrate-casein
hydrolysate beverage,
when compared to the
carbohydrate-only
beverage (P < 0.05). Postexercise plasma CK levels
and muscle soreness
ratings were significantly
elevated with ingestion of
the carbohydrate-only
beverage (P < 0.05), but
not with carbohydratecasein hydrolysate
beverage. These findings
suggest that the addition
of casein hydrolysate to a
carbohydrate beverage
significantly improves late
time-trial cycling
performance and
attenuates post-exercise
elevations in plasma CK
and muscle soreness.
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Influence of
protein
hydrolysate
dosage on
effects of
carbohydrate
and protein
ingestion during
exercise (Moore
et al., 2009)

To compare the
effects of
carbohydrate
beverages with
varying amounts of
protein hydrolysate
content on
endurance exercise
and markers of
muscle disruption.

10 trained male
cyclists and
runners: 25.7 +
3.4 yr, 72.6 +
3.2 kg, 51.7 +
2.6 ml/kg/min
(bike VO2peak),
54.3 + 2.3
ml/kg/min
(treadmill
VO2peak)

Subjects performed three
simulated duathlons,
consisting of an 8 km
treadmill run at 80%
VO2max, simulated 50
km cycle ergometer ride
at 70% VO2max, and
subsequent treadmill run
at 80% VO2max until
fatigue. Subjects were
administered 1.4 L of
randomly assigned
carbohydrate-only
beverage (6%),
carbohydrate + 1%
protein hydrolysate
beverage, or
carbohydrate + 2%
protein hydrolysate
during the cycle exercise.
Subsequent trials were
performed 6 – 10 days
apart with the alternate
treatment beverages.

Added Protein
Maintains
Efficacy of a
LowCarbohydrate
Sports Drink
(MartinezLagunas et al.,
2010)

To investigate the
aerobic capacity
characteristics of
an isocaloric
carbohydrateprotein beverage,
and a low-calorie
carbohydrateprotein beverage
against a 6%
carbohydrate
sports beverage.

12 (5 females
and 7 males)
trained cyclists
(28.3 + 1.4 yr,
65.7 + 2.3 kg,
57.3 + 2.7
ml/kg/min),

Subjects performed four
separate rides between 55
– 75% VO2max for 2.5
hours, and then at 80%
VO2max until fatigue.
Subjects were randomly
administered 255.4 + 9.1
ml of a placebo, a
carbohydrate only (6%)
beverage, a higher
dosage of carbohydrate
(4.5%) and protein
(1.15%) beverage, and a
lower dosage of
carbohydrate (3%) and
protein (0.75%) beverage
every 20min. Subsequent
trials were performed 7
days apart with alternate
treatment beverages.

The time to exhaustion
was significantly longer in
the subsequent treadmill
run with ingestion of the
carbohydrate + 1% protein
hydrolysate beverage, than
with the carbohydrateonly beverage (P < 0.05).
Post-exercise plasma CK
levels were significantly
lower with ingestion of the
carbohydrate + 2% protein
hydrolysate beverage, than
the other two treatments.
Post-exercise muscle
soreness ratings were
significantly lower with
ingestion of the
carbohydrate + 2% protein
hydrolysate, than with the
carbohydrate-only
beverage. The decline in
pre- to post-exercise peak
isometric force (MVC)
was significantly greater
with the carbohydrateonly ingestion, than the
other two treatments.
These findings suggest the
addition of small amounts
of protein hydrolysate to a
carbohydrate beverage
improves time to fatigue
in endurance exercise,
whereas a larger amount
of protein hydrolysate
attenuates muscle damage
associated with heavy
endurance exercise.
The times to exhaustion
were significantly longer
in the carbohydrate-only,
high and low dosages of
carbohydrate-protein
beverages, than the
placebo (P < 0.05), with
no significant differences
between the 3 treatments.
These 3 treatments also
reported elevated blood
glucose, plasma insulin,
carbohydrate oxidation,
and lower levels of free
fatty acids, rates of fat
oxidation, RPE compared
to the placebo. This study
suggests adding protein to
sports recovery drinks is
effective in enhancing
aerobic capacity, while
limiting carbohydrate and
caloric intake.
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Table 2.2: Carbohydrate and Protein and Post-Exercise Recovery.
Articles
Effects of a
carbohydrateprotein beverage
on cycling
endurance and
muscle damage
(Saunders, Kane,
and Todd, 2004)

Recovery from
run training:
efficacy of a
carbohydrateprotein
beverage?
(MillardStafford et al.,
2005)

Problem/Question
studied
To compare the
effects of a
carbohydrateprotein beverage
against a
carbohydrate-only
beverage on
cycling endurance
performance and
post-exercise
muscle damage.

Participants

Procedures

Findings

15 trained male
cyclists (20.9 +
3.3 yr, 73.3 +
6.4 kg, 52.6 +
10.3 ml/kg/min)

Subjects performed two
trials of cycle ergometry
to exhaustion (at 75%
and 85% VO2peak
respectively, 12 – 15 hr
apart). Subjects were
administered 1.8 ml/kg
bodyweight of randomly
assigned carbohydrate or
carbohydrate-protein
beverage every 15
minute during exercise,
and 10 ml/kg bodyweight
of the same treatment
post-exercise. The
protocol was repeated 7 –
14 days later with the
other treatment beverage.

To determine if the
increased calories
from protein
content or
additional
carbohydrate
content provide
ergogenic benefits
over traditional
CHO sports drinks
during recovery
from heavy aerobic
exercise.

8 (5 females and
3 males) trained
endurance
runners (28.6 +
6.6 yr, 59.3 +
8.1 kg, 56.5 +
5.9 ml/kg/min)

Subjects performed a 21
km outdoor run at 70%
VO2max, followed
immediately by a run to
fatigue at 90% VO2max
on a treadmill. Subjects
were then administered
one of three treatments
during a 2 hour recovery
period: a carbohydrate
(8%) and protein (2%)
beverage, a isocaloric
10% carbohydrate
beverage, or a
commercially available
6% carbohydrate drink.
Subjects then performed
the treadmill run to
fatigue after 2 hours, and
were administered the
same test beverage postexercise. The subjects
finally performed a 5 km
time trial 24 hours later.
Subsequent trials were
performed at least 7 days
apart with the alternate
treatment beverages.

The time to exhaustion
was significantly longer in
the subsequent
performance ride with
consumption of the
carbohydrate-protein
beverage, when compared
to the carbohydrate-only
beverage (P < 0.05). Peak
post-exercise CK levels
(12 – 15 hr after the initial
ride) were significantly
reduced with ingestion of
the carbohydrate-protein
beverage. These findings
demonstrate significant
improvements in
subsequent cycling time to
exhaustion and reductions
in muscle damage in
cyclists with the addition
of protein calories in
carbohydrate beverages.
Blood glucose and insulin
were significantly elevated
during the 2 hour recovery
period with ingestion of
the isocaloric 10%
carbohydrate beverage (P
< 0.05). There were no
significant improvements
from the first to second
run to fatigue, or the 24
hour 5 km time trial with
all three treatment
beverages. There were no
significant differences in
plasma CK levels in all
three treatment beverages.
Muscle soreness ratings
were significantly lower
with the carbohydrateprotein beverage,
compared to the isocaloric
10% carbohydrate drink.
These findings suggest
that while additional
calories from carbohydrate
or protein above those
provided in commercially
available drinks do not
improve subsequent
endurance performance
after recovery; the
additional protein content
may help to attenuate
muscle soreness.
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Chocolate milk
as a postexercise
recovery aid
(Karp, 2006)

To determine the
efficacy of
chocolate milk as a
recovery beverage
on subsequent
endurance
performance
following
glycogen-depleting
exercise.

9 trained male
cyclists (22.1 +
2.0 yr, 73.0 +
4.6 kg, 65.0 +
9.0 ml/kg/min)

The influence of
carbohydrate
and protein
ingestion during
recovery from
prolonged
exercise on
subsequent
endurance
performance
(Betts et al.,
2007)

To determine if the
potential ergogenic
benefit of
combined
carbohydrateprotein ingestion
during recovery
from heavy
endurance exercise
is due to the
protein content
itself or from the
additional calories.

6 trained male
endurance
runners (21 + 3
yr, 72.6 + 8.4
kg, 61.4 + 7.3
ml/kg/min)

Subjects performed three
separate glycogen
depleting trials at 90, 80,
70% of their maximal
power for 2 min
intervals on the cycle
ergometry, followed by
a subsequent
performance ride to
exhaustion at 70%
VO2max after a 4 hr
recovery. Subjects were
randomly administered
isovolumic amounts of
low-fat chocolate milk, a
fluid replacement drink,
or a carbohydrate
replacement drink
immediately postexercise and at 2 hr into
the recovery period.
Subsequent trials were
performed at least 7 days
apart with the alternate
treatment beverages.
Subjects performed three
separate trials of 90 min
treadmill run at 70%
VO2max. Subjects were
then administered one of
three treatments at 30
min intervals during a 4
hour recovery period: a
carbohydrate and whey
protein isolate beverage,
a lower carbohydrate
concentration beverage
(0.8 g per kg of
bodyweight), or a higher
carbohydrate
concentration beverage
(1.1 g per kg body
mass). Following
recovery, subjects then
performed a run to
exhaustion at 70%
VO2max. Subsequent
trials were performed at
least 7 days apart with
the alternate treatment
beverages.

The times to exhaustion
and total work performed
in the subsequent ride
were significantly greater
with the ingestion of the
low fat chocolate milk and
the carbohydrate
replacement drink,
compared to the fluid
replacement beverage (P <
0.05). There were no
significant differences in
heart rate and RPE in the
subsequent ride, as well as
in post-exercise blood
lactate for the glycogen
depleting exercise and
subsequent ride among all
three treatments. These
findings suggest that
chocolate milk is an
effective recovery
beverage for subsequent
endurance exercise.
The mean run times to
exhaustion following the 4
hour recovery were
significantly longer with
the ingestion of the
carbohydrate-protein
beverage, and the higher
carbohydrate dosage drink
(P = 0.05). The exercise
capacity during the run
time to exhaustion was
significantly improved
with ingestion of the
carbohydrate-protein
beverage, when compared
with a matched quantity of
carbohydrate alone (P =
0.02). There were no
significant differences in
time to exhaustion
between the carbohydrateprotein beverage and the
higher carbohydrate
concentration beverage.
These findings suggest
that additional calories
from protein or
carbohydrate content in
recovery beverages
prolongs time to
exhaustion and improves
exercise capacity in
subsequent endurance
performance, regardless of
the origin of the additional
energy source (sucrose or
whey protein isolate).
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Increased
carbohydrate
oxidation after
ingestion
carbohydrate
with added
protein (Betts et
al., 2008)

To examine the
metabolic impact
of post-exercise
carbohydrateprotein supplement
ingestion between
two running trials
performed in the
same day.

6 endurance
trained males
(22 + 1 yr, 73.8
+ 6.7 kg, 61 + 6
ml/kg/min)

Subjects performed two
separate trials of 90 min
treadmill run at 70%
VO2max. Subjects were
then administered either
a carbohydrate and whey
protein isolate solution,
or a carbohydrate-only
solution at 30 min during
a 4 hour recovery
period. Following
recovery, subjects then
performed a 60 min
treadmill run at 70%
VO2max. The entire
protocol was repeated 14
days later with the other
treatment beverage.

Effects of an
Amino Acid–
Carbohydrate
Drink on
Exercise
Performance
After
ConsecutiveDay Exercise
Bouts
(Skillen et al.,
2008)

To examine the
two week effects
of daily combined
carbohydrate and
amino acid
supplementation
on exercise
performance,
muscle damage,
and muscle
soreness from
consecutive bouts
of cycling
endurance
performance.

12 trained male
cyclists and triathletes (28.5 +
2.1 yr; 73.8 +
4.0 kg and 60.8
+ 1.9 ml/kg/min
during
carbohydrateonly treatment;
73.6 + 4.1 kg
and 60.2 + 2.1
ml/kg/min
during
carbohydrateamino-acid
treatment

Subjects performed a 90
min cycle ride at 70%
VO2peak, followed by a
ride to exhaustion at
85% VO2max. Subjects
were then supplemented
with a 3.6%
carbohydrate and 1%
amino acid beverage, or
a 4.6% isocaloric
carbohydrate-only
beverage for 2 weeks.
Subjects then repeated
the above cycle rides for
2 consecutive days after
the 2 weeks of
supplementation. The
entire protocol was
repeated 14 days later
with the other treatment
beverage.

The serum insulin
concentrations and median
insulinemic responses
were significantly higher
with the carbohydrateprotein solution (P = 0.02,
P = 0.04 respectively).
Whole-body carbohydrate
oxidation was
significantly higher during
the subsequent run with
the carbohydrate-protein
solution (P < 0.01). These
findings suggest that the
addition of protein content
in a carbohydrate recovery
beverage may increase the
oxidation of extramuscular
carbohydrate sources
without altering the rate of
muscle glycogen
degradation during
subsequent endurance
performance.
The time to exhaustion
between the 1st and 2nd
consecutive rides
decreased significantly
with the carbohydrateonly treatment, and
increased significantly
with the carbohydrateamino acid treatment (P <
0.05). The decrease in
vertical jump height on the
2nd consecutive day was
significantly attenuated
with the carbohydrateamino acid treatment (P <
0.05). Plasma CK levels,
total fatigue score, and
mood disturbance were
significantly lower on the
2nd consecutive day with
the carbohydrate and
amino acid beverage.
These findings suggest
that the addition of amino
acids to a carbohydrate
beverage after consecutive
day exercise bouts may
help maintain subsequent
endurance performance,
reduce muscle damage,
and decrease fatigue.
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Effect of dietary
protein content
during recovery
from highintensity cycling
on subsequent
performance and
markers of
stress,
inflammation,
and muscle
damage in welltrained men
(Rowland, 2008)

To examine the
effects of a high
carbohydrate,
protein enriched
post-exercise
recovery diet on
subsequent cycling
endurance
performance.

12 trained male
cyclists (34 + 10
yr, 75.9 + 4.3
kg, 4.9 + 0.6
L/min)

Subjects performed 3
high-intensity rides over
4 days: Day 1 comprised
of 2.5 hour intervals, and
days 2 & 4 comprised of
repeat-sprint
performances, with day 3
as a recovery day.
Subjects were
administered either the
protein-enriched diet, or
the control diet (equal
servings of protein and
fat) 4 hours post-exercise
on days 1 & 2. The entire
protocol was repeated 14
days later with the other
treatment diet.

Recovery from a
cycling time trial
is enhanced with
carbohydrateprotein
supplementation
vs. Isoenergetic
carbohydrate
supplementation.
(Berardi et al.,
2008)

To examine the
effects of ingesting
a liquid
carbohydrateprotein supplement
during recovery
from a cycling
time trial on the
subsequent 60 min
ride on the same
day, against an
isoenergetic liquid
carbohydrate
supplement.

15 trained male
cyclists: 7
receiving
carbohydrateprotein
supplementation
(32.43 + 8.85 yr,
74.76 + 9.39 kg)
and 8 receiving
carbohydrateonly treatment
(34.00 + 9.74 yr,
78.98 + 8.21 kg)

Subjects performed a
cycle time trial for 60
min. The distance
covered was recorded.
Subjects were then
administered 1 L of
carbohydrate-protein or
carbohydrate only liquid
supplement at 10/60/120
min post-exercise.
Following 6 hours of
recovery, subjects
repeated the 60 min cycle
time trial.

The mean sprint power
was significantly higher
on day 4 (4.1%, P < 0.05),
with the protein-enriched
diet. Overall plasma CK
levels throughout the 4
days may experience a
possible reduction with
the protein-enriched diet,
and were substantially
lower on day 4 before
exercise (P = 0.08). These
findings suggest that while
the addition of protein
content in a post-recovery
diet may not confer shortterm (15 hour) benefits, it
may improve delayed (60
hour) subsequent highintensity sprint
performance and attenuate
delayed muscle damage.
The decrease in distance
covered and decrease in
power output during the
subsequent time trial were
significantly reduced in
the carbohydrate-protein
supplement group. The
rate of fat oxidation was
significantly higher in the
carbohydrate-protein
group (P < 0.05), despite a
higher average workload.
These findings suggest
that ingestion of a liquid
carbohydrate-protein
supplement post-exercise
increases fat oxidation,
increases recovery and
improves subsequent
endurance performance in
a cycling time trial.

17
Improved
endurance
capacity
following
chocolate milk
consumption
compared with 2
commercially
available sport
drinks (Thomas,
Morris, and
Stevenson,
2009)

To examine the
effects of 3
isocaloric recovery
beverages on
subsequent
endurance
performance
following glycogen
depleting exercise

9 trained male
cyclists (25.4 +
8.0 yr, 72.8 +
8.4 kg, 4.3 + 0.4
L/min)

Subjects performed three
separate glycogen
depleting trials at 90, 80,
70, and 60% of their
maximal power for 2
min intervals on the
cycle ergometry,
followed by a subsequent
performance ride to
fatigue at 70% maximal
power after a 4 hr
recovery. Subjects were
randomly administered a
1 g/kg bodyweight of
carbohydrate
replacement drink, an
isovolumic amount of
fluid replacement drink,
or an isocaloric amount
of chocolate milk
immediately postexercise and at 2 hr into
the recovery period.
Subsequent trials were
performed at least 7 days
apart with the alternate
treatment beverages.

The time to exhaustion
was significantly longer
with ingestion of the
chocolate milk, than the
carbohydrate replacement
and fluid replacement
beverages (P < 0.05). This
finding suggest s that
when matched for caloric
content with a
carbohydrate replacement
drink, chocolate milk is an
effective recovery
beverage for subsequent
endurance exercise of
moderate intensity.
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Table 2.3: Genotypes and Sport Performance.
Articles
Elite endurance
athletes and the
ACE I allele –
the role of genes
in athletic
performance
(Gayagay et al.,
1998)

Human
angiotensin Iconverting
enzyme gene
and endurance
performance
(Myerson et al.,
1999)

Problem/Question
studied
To identify genetic
markers in the
renin-angiotensin
pathways that is
associated with
cardiovascular
performance.

To examine the
frequency
distribution of the
ACE I allele in
elite distance
runners and other
elite athletes.

Participants

Procedures

Findings

64 Australian
national rowers
(43 males, 21
females), and
118 controls

Blood samples were
collected and DNA
extractions were
performed for
genotyping analysis of
the RAS polymorphisms.
The ACE gene insertion
(I) and deletion (D)
polymorphism were
detected by polymerase
chain reaction conditions.

495 British elite
athletes: 91
distance runners
(48 males, 43
females), 404
athletes from 19
non-endurance
dependent
disciplines (219
males, 185
females), and
1906 controls.

Subjects‟ DNA were
extracted from the buccal
cells contained in 10 ml
of saline mouthwash
(0.9% sodium chloride
solution). The ACE I and
D polymorphisms were
identified by polymerase
chain reaction
amplification of the
polymorphic region.

The rowers exhibited
significantly higher
frequency of the ACE I
allele (P > 0.02), and
significantly higher
genotypic distributions of
the homozygous ACE II
genotype (P = 0.03) than
the controls. There was a
corresponding decreased
frequency of the ACE D
allele in the rowers. These
findings suggest that a
genetic factor associated
with the ACE I allele may
confer beneficial effects in
human cardiovascular
performances.
There is a significant
linear trend of increasing
frequency (P = 0.009) in
the ACE I allele with
primarily anaerobic
athletes (< 200 m), mixed
aerobic and anaerobic
athletes (400 – 3000 m),
and primarily aerobic
athletes (> 5000 m). The
frequency of the ACE I
allele was not significantly
different among the nonendurance athletes from
and the 19 disciplines, and
the controls (P = 0.526).
These findings show that
the frequency of the ACE
I allele is higher in among
elite distance runners, and
may increase with the
distance run. This suggests
that the ACE I allele is
positively associated with
elite endurance
performance.

19
ACTN3
genotype is
associated with
human elite
athletic
performance
(Yang et al.,
2003)

To examine the
effects of the
ACTN3 genotype
on human athletic
performance, and
determine the
influence of the
ACTN3 genotype
on variations in
muscle function.

301 white elite
athletes: 107
sprint athletes
(72 males, 35
females), 194
endurance
athletes (122
males, 72
females), and
436 controls
(134 males, and
292 females).

Blood samples were
collected and DNA
extractions were
performed for ACTN3
genotyping.

Mitochondrial
DNA and
ACTN3
genotypes in
Finnish elite
endurance and
sprint athletes
(Niemi and
Majammaa,
2005)

To examine
mtDNA
haplogroup and
subhaplogroup
frequencies and
differences in elite
Finnish sprinters
and endurance
runners, and to
assess the potential
of ACTN3
genotypes as a
confounding
variable.

141 Finnish elite
track and field
athletes: 52
endurance
athletes (800m –
marathon, or
walking), and 89
sprinters
(100/400m or a
field event).

Blood samples were
collected and DNA
extractions were
performed for MtDNA
haplogroup and
subhaplogroup analyses,
and ACTN3 genotyping.

There were significant
differences in allele
frequencies between sprint
athletes/endurance athletes
and controls (P < 0.010).
The allele frequency
variations between sprint
athletes and controls were
significant for males (P <
0.001) and females (P <
0.01). Sprint athletes
demonstrated a higher
frequency of the RR
genotype, a lower
frequency of the RX
genotype, and a lower
frequency of the XX
(ACTN3 null) genotype,
while endurance athletes
exhibited a slightly higher
frequency of the XX
genotype than controls.
There were significant
differences in allele
frequencies between sprint
and endurance athletes in
both males (P < 0.001)
and females (P < 0.05).
This suggests that the R
allele (ACTN3 positive)
confers a beneficial effect
on skeletal muscle
function in generating
forceful contractions at
high velocities.
There were significant
frequency differences in
mtDNA haplogroups
between Finnish sprinters
and endurance runners (P
= 0.039). The frequencies
of haplogroups J & K
were higher in the
sprinters, whereas the
frequency of haplogroup I
was higher in the
endurance runners. The
frequency of the ACTN3
577RR genotype was
higher in the sprinters,
whereas the frequency of
the ACTN3 577XX
genotype was higher in the
endurance athletes. The
577XX genotype was
inversely correlated to
best sprint times in the
sprinters (P = 0.03).
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ACTN3
genotype in
professional
endurance
cyclists (Lucia et
al., 2006)

To examine the
frequency
distribution of
ACTN3 in elite
cyclists, and
compare it against
elite endurance
runners, and
sedentary controls.

52 elite male
Caucasian
cyclists (26.9 +
0.4 yr, 178 + 0.8
cm, 67.4 + 0.9
kg), 50 elite
male Caucasian
endurance
runners (26.8 +
0.6 yr, 175.0 +
0.9 cm, 61.6 +
0.9 kg), and 123
sedentary
Caucasian males
(19 – 50 yr).

Gas-exchange
measurements were
obtained for the cyclists
and runners, from
maximal exercise tests to
fatigue on the cycle
ergometer and treadmill
respectively, as indices of
endurance performance.
Blood samples were
taken for DNA extraction
and ACTN3 genotyping
analysis (RR, RX, and
XX).

The effect of
AMPD1
genotype on
blood flow
response to
sprint exercise
(Norman et al.,
2008)

To determine if
deficiency in
skeletal msucle
myoadenylate
deaminase
(mAMPD), due to
variations in the
AMPD1 gene,
affect blood flow
response to high
intensity exercise.

15 subjects (21
– 32 yr)

Subjects perform a 30s
Wingate test against a
workload of 7.5% of
body weight. Peak and
average power over 5-s
periods, mean power
over entire 30-s duration,
and power decline were
recorded. Common
femoral artery blood flow
velocity and vessel
diameter were measured
pre- and 25 min postexercise. Blood samples
were collected
1/3/6/9/12/18/25 min
following exercise.

There were no significant
differences among elite
cyclists, elite runners, and
sedentary controls in all
three ACTN3 genotype
distributions (P > 0.05).
There was a trend for a
higher frequency of the
ACTN3 XX genotype in
elite cyclists. There were
no significant differences
between elite cyclists and
elite runners of each
genotype in the indices of
endurance performance:
VO2max, ventilatory
threshold (VT), and
respiratory compensation
threshold (RCT). This
suggests that the ACTN3
polymorphisms do not
confer advantages in
endurance performances.
Subjects homozygous and
heterozygous for AMPD1
34C>T alleles MM/NM
demonstrated significantly
lower mean power than
subjects homozygous for
the AMPD1 normal allele
NN (7.7 ± 0.6 W/kg vs 8.7
± 0.2 W/kg, P < 0.01) as
well as lower peak power,
and larger power declines.
MM/NM subjects
demonstrated a
significantly higher peak
femoral arterial blood
flow than NN subjects
(5.44 ± 0.41 l/min vs 4.10
± 0.31 l/min, P < 0.001),
and a significantly faster
normalization of arterial
blood flow post-exercise
(7.8 ± 1.1 min, vs 16.1 ±
1.4 min, P < 0.001). This
was associated with a
faster heart rate recovery
in MM/NM subjects postexercise. This suggests
AMPD1 mutations
contribute to diminished
mAMPD, which would
result in greater adenosine
accumulation, thereby
promoting exerciseinduced hyperaemia in
high-intensity exercise.
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An ACTN3
knockout mouse
provides
mechanistic
insights into the
association
between aactinin-3
deficiency and
human athletic
performance
(MacArthur et
al., 2008)

To examine the
mechanisms by
which the ACTN3
R577X
polymorphism
influences human
athletic
performance
through phenotypic
analysis of the
biochemical and
physiological
effects of ACTN3
deficiency in
knockout mice.

Mice models (79 wk), 43 males
(19 wild-type,
24 knockout –
ACTN3 null
allele), 83
females (39
wild-type, 44
knockout).

Grip strength was
measured. Body
composition was
determined by DEXA.
Transverse sections
of the quadriceps,
spinalis thoracis,
extensor digitorum
longus (EDL), and soleus
muscles were analyzed
for fiber type proportions
and measured for size.
Mitochondrial enzyme
levels were measured to
examine muscle
metabolic activity. Fasttwitch EDL muscles
were isolated to examine
differences in contractile
properties.

Average grip strength was
significantly lower in
knockout mice than wildtype mice (P = 0.007
males, P = 0.02 females).
Total body weight was
lower in male and female
knockout mice than the
wild-type mice. This was
attributed to loss of lean
mass rather than loss of fat
mass. Fast glycolytic type
IIb fibers responsible for
ACTN3 in wild-type mice
were significantly smaller
in the quadriceps (P <
0.05), and spinalis (P <
0.01) of knockout mice.
There were no significant
differences in the total
number of fibers in the
EDL. This suggests that
the reduction in muscle
mass in knockout mice
was attributed to reduction
in specific fiber size rather
than differences in fiber
type distributions. The
metabolic profile of
knockout mice exhibited
increases for enzymes in
the glycolytic pathway,
mitochondrial enzymes of
the tricarboxylic acid
cycle, electron transport
chain enzyme, and
mitochondrial enzymes
involved in fatty acid
oxidation. These changes
in muscle metabolism
suggest that in the absence
of ACTN3, there is a shift
from anaerobic towards
aerobic pathways, as well
as an increased reliance in
B-oxidation of fatty acids.
The twitch half-relaxation
times in fast-twitch EDL
muscles were significantly
longer in knockout mice
than wild-type mice (P =
0.007), and recovery from
fatigue induction as
determined by force
generation capacity was
greater in knockout mice
muscle. These changes in
contractile properties
suggest a shift in the
characteristics of fast
fibers towards slow fibers
with ACTN3 deficiency.

22
ACTN3 R577X
polymorphism
and Israeli toplevel athletes
(Eynon et al.,
2009)

To examine the
frequency
distribution of the
ACTN3 R577X
polymorphism
between Israeli
athletes and nonathletes, and
among different
sports (sprints and
endurance events)
at different levels
of competition (top
and national level)
among the athletic
Israeli population.

155 athletes
(35.9 + 12.2 yr),
119 males and
36 females, 74
distance runners
(20 top level, 54
national level)
and 81 sprinters
(26 top level, 55
national level).
240 controls,
170 males and
70 females.

Genomic DNA was
extracted from peripheral
blood leukocytes for
genotyping of the
ACTN3 R577X
polymorphism

The ACTN3 R577X
genotype and allele
frequencies were
significantly different
between sprinters and
distance runners (P =
0.00009, and P = 0.00007
respectively), and between
sprinters and controls (P =
0.00003, and P = 0.00002
respectively). The
genotype frequencies were
significantly different
between the distance
runners and controls,
while the differences in
allele frequencies between
distance runners and
controls demonstrated a
trend towards significance
(P = 0.08). Distance
runners exhibited a
significantly higher
proportion of the XX
genotype than sprinters (P
= 0.005), and controls (P =
0.006). The R allele was
more frequent in top level
sprinters than national
level sprinters. This
suggests that ACTN3 R
allele may be associated
with top level sprint
performance. There were
no significant differences
in genotype and allele
frequencies in top level
and national level
endurance athletes (P =
0.7). This suggests that the
ACTN3 X allele and XX
genotypes may be additive
rather than critical to
endurance performance.
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Table 2.4: Genotypes and Muscle Performance.
Articles
Angio-tensinconverting
enzyme
genotype affects
the response of
human skeletal
muscle to
functional
overload
(Folland et al.,
2000)

The ACE gene
and muscle
performance
(Williams et al.,
2000)

Problem/Question
studied
To examine the
effect of the ACED allele on the
response of human
skeletal muscle to
functional overload
from strength
training.

To examine
associations
between ACE
genotypes and
changes in the
mechanical
efficiency of
skeletal muscle
following physical
training.

Participants

Procedures

Findings

33 males (21.4 ±
0.5 yr, 75.9 ±
2.1 kg, 180 ± 1
cm) body mass
index, 23.3 ±
0.6 kg/m2)

Subjects participated in a
9-week strength training
program of the
quadriceps muscle, with
each leg randomly
assigned to isometric or
dynamic strength
training. Epithelial cells
were collected through
saline mouth rinses for
genotyping analysis.
Baseline and posttraining isometric
strength (MVC) of the
quadriceps muscle was
measured. Additional
strength measurements
include peak isokinetic
torque at four angles and
three velocities

58 Caucasian
army recruits
(19.4 0.3 yr,
1.78 0.01 m,
71.3 1.2 kg)

Subjects participated in a
primarily aerobic 11week physical training
program. Blood samples
were taken for DNA
extraction and
genotyping analysis.
Baseline and posttraining steady state
oxygen uptake (VO2) and
respiratory exchange
ratio (RER) were
measured on a cycle
ergometer exercise to
determine the efficiency
of muscular contraction
(delta efficiency).

Subjects with the ACE-D
allele demonstrated
significant improvements
in quadriceps muscle
strength (MVC) with
isometric strength training
(P < 0.05), and
demonstrated a trend for
greater increases in all
isokinetic strength
measurements. The
interaction between
training and genotype was
non-significant with
dynamic strength training.
The interaction between
genotype and training was
consistent in all strength
measurements for both
types of training (ACE ID
> ACE DD > ACE II).
This suggests that the
renin-angiotensin system
may play a role in the
response of skeletal
muscle to functional
overload via the ACE ID
polymorphism.
Baseline delta efficiency
was independent of ACE
genotypes (P = 0.59).
Subjects homozygous for
ACE II genotype
documented significantly
higher post-training delta
efficiency than baseline (P
< 0.01), and significantly
higher increases in delta
efficiency than subjects
homozygous for ACE DD
genotype (P < 0.025). This
suggests that the ACE II
genotype may be
associated with an
improved mechanical
efficiency in trained
skeletal muscles due to
possible increases in slowtwitch muscle fibers,
which are more efficient
in slow contractions.
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The I allele of
the angiotensinconverting
enzyme gene is
associated with
an increased
percentage of
slow-twitch type
I fibers in human
skeletal muscle
(Zhang et al.,
2003)

To determine the
association
between ACE
genotypes and
skeletal muscle
fiber type
distribution.

41 untrained
subjects (31
males, 10
females, 24 ± 3
yr)

Blood samples were
taken for DNA extraction
and genotyping analysis.
Skeletal muscle samples
were taken from the left
vastus lateralis, and fiber
type distribution was
classified into type I, IIa
and IIb.

ACTN3
genotype is
associated with
increases in
muscle strength
in response to
resistance
training in
women
(Clarkson et al.,
2005)

To determine the
associations
between ACTN3
and muscle size,
isometric strength,
and dynamic
strength following
a 12-week
resistance training
program.

602 subjects (18
– 40 yr), 247
males and 355
females, 469
Caucasians, 28
AfricanAmericans, 25
Hispanics, 55
Asians

Subjects participated in a
12-week resistance
training program of their
non-dominant elbow
flexor/extensor. Blood
samples were taken for
DNA extraction and
genotyping analysis.
Baseline and posttreatment maximal
isometric (MVC) and
dynamic (1-RM)
strength, and muscle size
(cross-section area) of
the elbow flexor were
measured.

Subjects homozygous for
ACE II genotype
exhibited significantly
higher percentages of type
I fibers, and significantly
lower percentages of type
IIb fibers compared with
subjects homozygous for
ACE DD genotype.
Across the genotype
groups, there are
significant linear trends (P
< 0.01) for decreased
distribution of type I fibers
(ACE II > ACE ID > ACE
DD), and increased
distribution of type IIb
fibers (ACE II < ACE ID
< ACE DD). This
demonstrated that the
ACE-I allele is associated
with higher ratios of type I
muscle fibers.
No significance between
ACTN3 genotype and
muscle size/strength in
male subjects. Female
subjects homozygous for
the mutant ACTN3 XX
allele exhibited
significantly larger gains
in absolute and relative 1RM (P < 0.05). ACTN3
genotype is associated
with 2% of baseline MVC
and 1-RM strength gain (P
= 0.01). This suggests
ACTN3 may contribute to
genetic variations in
muscle response and
adaptation to resistance
exercise.
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ACE ID
genotype and the
muscle strength
and size
response to
unilateral
resistance
training
(Pescatello et al.,
2006)

To examine
associations among
ACE insertion (I)
and deletion (D)
polymorphisms
and the response to
a 12-week
resistance training
program.

631 subjects
(24.2 + 0.2 yr),
264 (41.8%)
males and 367
(58.2%)
females, 79.5%
Caucasians,
4.1% AfricanAmericans,
4.6% Hispanics,
8.1% Asians,
3.3% other

Subject participated in a
12-week unilateral upperarm resistance training
program of their nondominant arms (5
exercises: bicep preacher
curl, biceps concentration
curl, standing biceps curl,
overhead triceps
extension, and triceps
kickback). Exercise
intensity started at 65 –
75% of 1-RM (3 sets x
25 repetitions), and was
increased at week 5 (75 –
82% 1-RM, 3 sets x 8
repetitions) and week 10
(83 – 90% 1RM, 3 sets x
6 reps). Blood samples
were taken for DNA
extraction and
genotyping analysis.
Baseline and posttraining maximal
isometric (MVC) and
dynamic (1-RM)
strength, and muscle size
(cross-section area) of
the elbow flexor were
measured.

ACTN3
(R577X)
genotype is
associated with
fiber type
distribution
(Vincent et al.,
2007)

To examine the
associations
between ACTN3
polymorphisms
and skeletal
muscle fiber type
distribution, and
fast-velocity knee
extension strength.

90 males (21.7 +
2.3 yr, 73.3 +
8.6 kg)

Blood samples were
taken for DNA extraction
and genotyping analysis.
Isometric knee extensor
strength (45°) was
measured at different
dynamic velocities (100
– 300°/s). Skeletal
muscle samples were
taken from the right
vastus lateralis, and fiber
type distribution was
classified into type I, IIa
and IIx. Protein content
in the different fiber
types was determined
with assays.

Absolute and relative
MVC increases were
greater for ACE II/ID
genotypes than ACE DD
genotype in nondominant/trained arms (P
< 0.05), as well as
dominant /untrained arms
(P < 0.05) post-training.
Absolute and relative
increases in 1-RM and
cross-section area were
independent of ACE
genotype groups in nondominant arms posttraining (P >or = 0.05).
Absolute and relative
increases in 1-RM and
cross-section area were
greater for ACE DD/ID
genotypes than ACE II
homozygotes in dominant
arms post-training (P <
0.05). There were no
differences in baseline
muscle strength and size
among the ACE genotype
groups. This suggests that
the ACE ID genotype may
be more associated with
the contralateral education
and learning effects of
unilateral resistance
training, than with
muscular strength and
hypertrophic adaptations.
Subjects homozygous for
the ACTN3-R allele
recorded significantly
higher relative dynamic
quadriceps torques at
300°/s, compared with
subjects homozygous for
XX (P < 0.05). Subjects
homozygous for RR
exhibited significantly
greater distribution of type
IIx fibers than subject
homozygous for XX (P <
0.05). -actinin-3 protein
content was higher in type
IIx than in type IIa fibers.
This suggests the
differences in skeletal
muscle fiber type
characteristics between the
two ACTN3 genotype
groups are significant, and
the association between
the ACTN3 polymorphism
and fiber type distribution
may affect muscle power.
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ACE genotype
and the muscle
hypertrophic and
strength
responses to
strength training
(Charbonneau et
al., 2008)

To examine
associations
between ACE
genotypes groups,
muscle
phenotypes, and
strength responses
to strength training
in older adults.

243 subject (50
– 85 yr), 81
males, 139
females, 147
Caucasians, 81
AfricanAmericans

Subjects participated in a
10-week unilateral knee
extension training of
their dominant leg. Blood
samples were taken for
DNA extraction and
genotyping analysis.
Baseline and posttraining muscle strength
of the knee extensor (1RM) and quadriceps
muscle volume (MV)
were measured.

Angiotensinconverting
enzyme
genotype affects
skeletal muscle
strength in elite
athletes
(Costa et al.,
2009)

To examine the
association
between ACE
genotype groups
and skeletal
muscle baseline
strength in elite
male and female
athletes.

58 elite athletes:
35 swimmers
(19 males, 16
females, 18.8 ±
3.2 yr), 23 triathletes (15
males, 8 female,
18.7 ± 3.0 yr).
The athletes
were Olympic
candidates and
further classified
either as short
(< 200m), or
middle (400m –
1500m) distance
athletes

Baseline blood samples
were collected for DNA
extraction and ACE
genotyping. Baseline
bilateral grip strength,
and maximum height in
squat jump and counter
movement jump were
recorded.

Baseline MV in subjects
homozygous for ACE DD
genotype was significantly
greater in both trained (P
= 0.02) and untrained legs
(P = 0.01) than subjects
homozygous for ACE II
genotype. There were no
significant differences in
baseline 1-RM in both
trained and untrained legs
among the ACE genotype
groups. Post-training 1RM (P < 0.01) and MV (P
< 0.01) improved
significantly among all
ACE genotype groups,
and there were no
genotype differences in
post-training 1-RM and
MV in both legs. This
suggests that there is no
association among the
ACE genotype groups for
muscle strength and
muscle volume
adaptations to strength
training in older adults,
and that the ACE
genotype is more
associated with baseline
differences in muscle
volume.
Male and female subjects
homozygous for ACE DD
alleles demonstrated
significantly higher right
grip strength (P < 0.05)
compared to subjects
homozygous to ACE II
allele. Short distance
subjects of both genders
recorded higher scores in
most strength
measurements (P <0.05)
than middle distance
subjects. Female subjects
heterozygous for ACE ID
allele recorded
significantly higher right
grip strength (P = 0.032)
and counter movement
jump (P = 0.048) than
those homozygous for
ACE II allele. This
suggests that ACE D allele
is associated with baseline
muscle strength in elite
athletes, especially elite
female athletes.
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Table 2.5: Genotypes and skeletal muscle damage/recovery.
Articles
The
relationships
among IGF-1,
DNA content,
and protein
accumulation
during skeletal
muscle
hypertrophy
(Adams and
Haddad, 1996)

Problem/Question
studied
To examine the
time course
between increases
in IGF-1 peptide
and mRNA
expression, and
skeletal muscle
hypertrophy.

Participants

Procedures

Findings

128 female
Sprague-Dawley
rats (205 + 3 g).

60 rats were
hypophysectomized to
reduce circulating IGF-1
and GH. The normal and
hypophysectomized rats
were grouped into
overload and control
groups. Bilateral removal
of the gastrocnemius and
soleus muscles was
performed to overload
the plantaris muscles in
the overload groups. At
3/7/14/28 days postsurgery, control and
overloaded rats were
killed with an overdose
of pentabarbitol sodium.
Plant muscles from both
legs were excised for
subsequent analysis.

Peak muscle IGF-1
peptide levels in normal/
hypophysectomized rats
occurred after 3/7 days of
overloading, and were
demonstrated a 4.1/6.2fold increase against
controls. These increases
in muscle IGF-1 preceded
the following hypertrophic
response: Plantaris mass,
myofiber size, and protein
to bodyweight ratio were
significantly higher with
overloading in normal and
hypophysectomized rats
than the control groups (P
< 0.05). The total DNA
content of the plantaris
muscles increased
significantly in normal
and hypophysectomized
rats with overloading. The
relationship between IGF1 peptide levels and total
DNA content in the
plantaris muscle was
significant in normal (r =
0.53, P = 0.0001) and
hypophysectomized (r =
0.73, P > 0.0001) rats with
overloading. These
findings suggest that rats
with normal and severely
attuenated levels of IGF-1
increase their expression
of local IGF-1 as a
response to functional
overload, which may
contribute to the muscle
hypertrophy response,
through mobilization of
satellite cells to provide
increases in muscle DNA.
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Developmental
expression and
location of IGF-I
and IGF-II
mRNA and
protein in
skeletal muscle
(Gerrard et al.,
1998)

To examine the
role of IGF in
skeletal muscle
development in
vivo.

Twenty one
30/44/59/68/75/
89/109 day-old
porcine fetuses,
three 21 day old
neonatal pigs,
and three 6
month-old adult
pigs.

Muscle and tissue
samples were obtained
from the semi-tendinosus
of a limb and liver
respectively for mRNA
analysis. Muscle samples
were taken from the
contralateral pelvic limb
for in situ hybridization.

IGF-I restores
satellite cell
proliferative
potential in
immobilized old
skeletal muscle
(Chakravarthy,
Davis, and
Booth, 2000)

To examine the
effects of repeated
cycles of atrophy
and re-growth on
the capacity of
satellite cells to
replicate in aged
skeletal muscle.

30 pathogenfree Fischer
344/Brown
Norway
F1 hybrid
(FBN) male rats
(3/8/31 mo)
were used to
determine the
effects of
normal aging on
satellite cells,
and 36
pathogen-free
FBN male rats
(25 – 26 mo,
523 + 10 g)
were used to
determine the
effects of
repeated bouts
of atrophy and
re-growth on
muscle mass,
satellite cells.

Muscle samples were
obtained from the
gastrocnemius in the hind
limbs bilaterally to
isolate and culture
satellite cells. Three
cycles of hind-limb
immobilization with
plaster casts and
intervening recovery
periods were
administered to promote
atrophy and re-growth in
skeletal muscle.

Peak levels of muscle
IGF-II occurred in 59 day
old porcine fetuses and
declined thereafter (P <
0.05). Maximal levels of
muscle IGF-I occurred
around birth (P < 0.05).
Expression of IGF-I and
IGF-II mRNA was
localized to developing
muscle fibers, as there was
little signal was found in
the surrounding
connective tissues. These
findings suggest that
IGF-I and -II are primarily
expressed and produced in
muscle cells within
developing muscle tissue,
and hence, support fetal
muscle development.
There were significant
losses in gastrocnemius
muscle mass and in the
proliferative potential of
the resident satellite cells
after one bout of
immobilization (P <
0.05), both of which did
not recover from their
decreased levels after
either the first 3-week or
subsequent 9-week
recovery period. The
infusion of IGF-I onto the
atrophied gastrocnemius
muscle for two additional
weeks after the 9-wk
recovery period rescued
46% of the lost muscle
mass and significantly
increased proliferation
potential of the satellite
cells (P < 0.05). These
findings demonstrate the
beneficial effects of local
infusion of IGF-I to
activate satellite cells in
atrophied muscles.
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Expression of
IGF-I splice
variants in
young and old
human skeletal
muscle after
high resistance
exercise
(Hameed et al.,
2003)

To examine the
acute effects of
resistance
weightlifting
exercise on the
different IGF-I
polymorphisms in
human skeletal
muscle.

8 young men
(29.5 ± 1.5 yr,
81.1 ± 2.4 kg,
179.3 ± 1.8 cm),
and 7 elderly
men (74.4 ± 1.8
yr, 74.7 ± 2.1kg,
177 ± 2.3 cm)

Subjects performed 10
sets of 6 repetitions of
single-leg knee extensor
exercise at 80 % of their
1-RM. Muscle biopsy
samples were taken from
the vastus laterialis of the
test leg and control leg
2.5 hr post-exercise.
Total RNA was extracted
from both test and
control muscle samples,
and transcribed into
cDNA. mRNA was
coded for ACTN, IGFIEa, IGF-IEc (MGF) and
MyoD.

Mice deficient in
plasminogen
activator
inhibitor-1 have
improved
skeletal muscle
regeneration
(Koh et al.,
2005)

To examine the
role of the
plasminogen
system in skeletal
muscle regulation
and regeneration,
and specifically, to
test if deficiency in
plasminogen
activator inhibitor1 (PAI-1), a
primary inhibitor
of urokinase-type
plasminogen
activator (uPA),
would improve
skeletal muscle
regeneration.

uPA and PAI-1
null mice

Mice were anesthetized
and isometric force
measurements were
recorded in situ. 10 ul of
cardiotoxin was injected
into three locations of the
extensor digitorum
longus muscle. Mice
were allowed to recover,
and isometric force
measurements were
recorded 1 – 20 days post
injection.

Resting levels of IGF-IEa
mRNA were significantly
higher than MGF mRNA.
There were no differences
in resting levels of MGF
mRNA and IGF-IEa
mRNA between the young
and elderly subjects. The
resting levels of MyoD
mRNA were significantly
higher in the elderly
subjects. With resistance
exercise, the levels of
MGF mRNA were
significantly higher in the
exercised legs than control
legs of the younger
subjects, but not the
elderly subjects. There
were no significant
differences in the levels of
IGF-IEA mRNA and
MyoD mRNA between
the control and exercised
legs in both subject groups
with resistance exercise.
The proportion of myosin
heavy chain II (MHC-II)
were significantly lower
(P < 0.05) in the
quadriceps of the elderly
adults. These findings
suggest that resistance
training attenuate the
MGF response in elderly
adults, whereas MGF and
IGF-IEa isoforms are
regulated differentially in
young skeletal muscle.
PAI-1 null mice exhibited
greater expression of
MyoD and developmental
protein, and more rapid
recovery of muscle
morphology, protein
levels, and function posttreatment compared to
wild-type mice. The
accelerated rate of
recovery in PAI-1 mice is
associated with greater
accumulation of
macrophages posttreatment. This suggests
inhibition of PAI-1 in
mice attenuates
plasminogen activator
activity, and stimulates
skeletal muscle
regeneration.
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ACTN3 and
MLCK genotype
associations with
exertional
muscle damage
(Clarkson et al.,
2005)

To examine if
variations in the
genes coding for
myofibrillar
proteins involved
in skeletal muscle
function influence
responses to
exertional muscle
damage through
eccentric resistance
exercise

157 subjects
(age of 24.1 ±
5.2 yr, height of
170.8 ± 9.9 cm,
body mass of
73.3 ± 17.0 kg),
78 males and 79
females, 115
Caucasians, 4
AfricanAmericans, 6
Hispanics, 20
Asians, 11
“other”

Subjects performed 50
maximal eccentric elbow
flexor contractions (2
sets x 25 repetitions, 5
min interval). Maximal
isometric strength
(MVC) was tested preand immediately postexercise and 4/7/10 days
post-exercise. Blood
samples were taken preand 4/7/10 days postexercise for CK and Mb
analysis, as well as DNA
extraction and
genotyping

ACE ID
genotype affects
blood creatine
kinase response
to eccentric
exercise
(Yamin et al.,
2007)

To determine the
role of the skeletal
muscle renninangiotensin system
(RAS), specifically
the ACE ID
genotype, in the
regulation of
exertional muscle
injury through
eccentric resistance
exercise.

70 physical
education
students (25 ± 3
yr, 171 ± 8 cm,
67 ± 10kg), 42
males and 28
females

Subjects performed 1 set
of 50 maximal eccentric
elbow flexor contraction
of their non-dominant
arm. Blood samples were
taken pre- and
3/24/48/72/96/120/168 hr
post-exercise for CK
activity and genotype
analysis

ACTN3 R577X is
associated with baseline
CK activity, and explained
3.5% of all variation
within baseline CK
activity; no association
with change in
strength/blood proteins
post exercise.
MLCK 49T (homozygous
rare allele found in 3.9%
of subjects): greater
increases in CK (28,934
U/l) and Mb (937 ng/ml).
MLCK C37885A
(heterozygous rare allele
found in 22.3% of
subjects): 57% strength
loss, greater increases in
CK.
The ACE ID genotype
was the most powerful
independent determinant
of peak CK activity (95%
confidence interval, P =
0.02). The homozygous
ACE II allele was
associated with the highest
peak CK activity (8,882 ±
2,361 U/l) and the largest
increase in CK activity
(8,735 ± 2,352 U/l). Peak
CK activity and increases
in CK activity were
intermediate in the
heterozygous ACE ID
allele (4,454 ± 1,105 U/l,
4,296 ± 1,108 U/l), and
lowest in the homozygous
ACE DD allele (2,937 ±
753 U/L, 2,778 ± 757 U/l).
This suggests that the
ACE II genotype may be
associated with the
development of exertional
rhabdomyolysis, whereas
the ACE DD genotype
may protect against
exercise-induced muscle
injury.
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IGF-II gene
region
polymorphisms
related to
exertional
muscle damage
(Devaney et al.,
2007)

To identify IGF
polymorphisms
associated with
exertional muscle
damage through
eccentric resistance
exercise.

151 subjects 73 males (25.3 ±
5.4 yr, 170.5 ±
7.9 cm, 81.9 ±
17.2 kg) and 78
females (22.8 ±
4.6 yr, 159.2 ±
6.8 cm, 64.5 ±
11.4 kg), 73%
Caucasians, 3%
AfricanAmericans, 4%
Hispanics, 13%
Asians, 7%
“other”

Subjects performed 50
maximal eccentric elbow
flexor contractions (2
sets x 25 repetitions, 5
min interval). Maximal
isometric strength
(MVC) was tested preand immediately postexercise as the criterion
measure. Muscle
soreness was assessed
pre and 3/4/7/10 days
post-exercise via a visual
analog scale. Blood
samples were taken preand 4/7/10 days postexercise for CK and Mb
analysis, as well as DNA
extraction and
genotyping

IGF-II G13790C
(homozygous rare allele
found in 18.6% of
subjects): 58% strength
loss immediately postexercise, increased serum
CK activity at 7 days postexercise (8818 U/l).
IGF-II G17200A
(homozygous rare allele
found in 11.0% of
subjects): 60% strength
loss immediately postexercise, increased CK
activity at 7 days postexercise (12261 U/l).
IGF2AS A1364C
(homozygous wild type
found in 36.2% of
subjects): 58% strength
loss, 50mm soreness.
IGF2AS G11711T
(homozygous wild type
found in 27.8% of
subjects): 56% strength
loss, 56mm soreness,
increase in blood CK
(17,160 U/l) and Mb (659
ng/ml).

Chapter III
Methods
Subjects
Fourteen endurance-trained male cyclists (18-45 yrs) were recruited from James
Madison University and the surrounding area. The inclusion criteria included a minimum
of three days a week of cycling for the past 2 months, and a peak aerobic capacity
(VO2peak) greater than 45 ml/kg/min. All subjects received a written consent form that
described the risks and benefits associated with the study. After a description of the
protocols, subjects signed the written consent form. James Madison University
Institutional Review Board approved the experiment design before data collection began.

Procedures
The study design consisted of a pre-testing/screening phase, familiarization trial,
and three treatment trials.

Pre-testing Phase
All potential subjects that met the study criteria completed the following
assessments.
Body Mass and Height
Subjects had their body weight measured to the nearest 0.1kg and height
measured to the nearest 0.5cm.
VO2peak/Wmax
Subjects completed an exercise test to determine their peak oxygen uptake
(VO2peak) and associated power output (Wmax). The test began with subjects riding
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a cycle ergometer at a self-selected pace, described as a “comfortable but not easy
pace for an hour long ride.” After subjects selected their initial workload, power
output was increased by 25 W every 2 minutes until the subject voluntary
requested to stop the test due to fatigue. Peak oxygen uptake and power output
were measured during the test to determine if subjects met entry criteria for the
study, and to establish intensities for subsequent exercise protocols.

Familiarization Trial
All subjects that met the inclusion criteria performed a familiarization trial within
two weeks of the pre-testing assessment. The purpose of the familiarization trial was to
determine if the exercise intensities were appropriate for each subject. The familiarization
trial also allowed subjects to become acclimated to the protocol and establish the
appropriate pace for the time-trial segment. Subjects were tested prior to the treatment
phase in order to alter workloads and to ensure they can complete the treatment trial.
Another purpose of the familiarization trial was to minimize any effects of learning and
the repeated-bout effect, in order to reduce error variance between treatment trials. All
subjects received the CHO recovery beverage during the familiarization trial (described
below). The treatment phases began 7 to 10 days following the familiarization trial. No
blood draws or muscle recovery measures were taken during the familiarization trial.

Treatment Phases
Treatment phases were similar to the familiarization trial with the addition of the
supplementation treatment provided during the trial, and the inclusion of blood draws and

34
muscle recovery measures. The treatment phase consisted of a glycogen-depleting
exercise, a recovery period and a subsequent time trial.
A visual timeline of events during each of the treatment phase is provided in
Figure 3.1 below.

Figure 3.1: Timeline for exercise trials and measurements of recovery.
PRE:
MS
MPEF
CK
MVC

Glycogen
Depleting
Trial

Post: 0.5HrPost: 2HrPost: 4HrPost:
MVC
IN
TB
MS
Subsequent
TB
GL
MPEF
Exercise
MVC
Trial

Post: 24HrPost:
MVC MS
TB
MPEF
CK
MVC

4 hours

24 hours
MS=Muscle Soreness, MPEF= Mental/Physical Energy/Fatigue, CK=Creatine Kinase,
MVC= Peak Isometric Torque, TB=Treatment Beverage, IN=Insulin, GL=Glucose

Glycogen-depleting exercise
Subjects performed a steady state warm-up for 10 minute at 60% Wmax. After the
initial 10 minutes of exercise, subjects completed a series of 2 minute highintensity intervals. The high-intensity intervals consisted of 2 minutes at 95%
Wmax at a cadence of 70 rpm, followed by 2 minutes at 50% Wmax. Once the
cadence dropped below 70 rpm, the workloads for the high-intensity intervals
were decreased to 85% Wmax, with the cadence remaining at 70 rpm. Once the
cadence dropped below 70 rpm again, the workload for the high-intensity
intervals was further decreased to 75% Wmax. The test was terminated when
subjects failed to maintain a cadence of 70 rpm at this intensity. This protocol was
designed to induce muscle glycogen depletion and moderate fatigue (Kuipers et
al., 1987). Based on similar findings from Karp et al (2006) and Van Loon et al
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(2000), the duration of the test was expected to last approximately 50-75 minutes,
with 30-45 minutes of high-intensity intervals. All subjects were permitted to
consume water ad libitum throughout the trial.

Recovery Period
Following the glycogen-depleting exercise there was a 4 hour period of recovery.
Subjects consumed 750 ml of a recovery beverage immediately following this
trial and again 2-hours post-exercise (see „treatment beverage‟ below for
description).

Subsequent Exercise Performance
After a 4 hour recovery period, subjects performed an endurance performance
trial on a computerized cycle ergometer (VeloTron, Racermate, Inc). The start of
the trial consisted of 20 minutes at a steady-state pace, with intensity
corresponding to 60% Wmax. The purpose of the steady state segment was to
assess steady-state substrate utilization, and to ensure depletion of muscle
glycogen. Following 20 minutes of steady-state exercise, subjects completed a
simulated 20 km time trial. The last 5 km of the course consisted an uphill
segment at 5% elevation. This was included in the protocol to allow an
assessment of late-exercise performance.
All trials were performed at ambient room temperature (70-72 oF). The subjects
were asked to void their bladders prior to all trials. A Windmere fan, set on
„medium‟ speed, was placed 2 meters from the handlebars of the ergometer for
cooling purposes during the trial. Water was provided ad libitum throughout all
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trials. Each subject was asked to provide maximal effort and treat each time trial
as a competitive event. For consistency, no verbal encouragement was provided to
the subjects during the time trial. The only feedback subjects received during the
trials regarding performance were distance remaining and distance completed.
Subjects were given at least one week between trials to ensure complete recovery.
Participants were allotted 14 days to complete a trial in the event of unrelated
illness or unforeseen circumstances, which occurred in four subjects.

Dependent measurements

Subsequent Exercise Performance
Exercise performance was measured using cycling time to completion for the 20
km time trial. Time was also recorded during the final 5km of the course.

Physiological Responses during Steady-State Exercise
Metabolic Measurements
Metabolic measurements were obtained during the glycogen-depleting trial and
during the steady-state segment of the subsequent performance trial using a
SensorMedics Spectra metabolic cart. These measurements were obtained after 3
minutes of cycling during the glycogen depleting trial (at 60% Wmax) and after 3
minutes of cycling during the subsequent performance trial (also at 60% W max).
Expired respiratory gases were collected for 5 minutes at each time point.
Average values were calculated using the final 3 minutes of each time period,
following 2 minutes of breathing equilibration. Measurements obtained from the
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expired gases included oxygen uptake (VO2), ventilation (VE), and respiratory
exchange ratio (RER).

Blood Glucose and Lactic Acid
Blood samples were obtained immediately prior to exercise, during the glycogendepleting trial (at minute 8) and exercise performance trial (at minute 8), and 30
minutes post-exercise. Approximately 0.5 ml of blood was collected during each
point via a finger-stick. An automated analyzer (YSI 2300 STAT glucose/lactate
analyzer) determined glucose and lactate levels.

Serum Insulin
Thirty minutes after consuming the recovery beverage, 5 ml of blood was
collected using a venous blood draw from an antecubital vein. The blood was
collected in SST clot agent Vacutainer® tubes, centrifuged, and serum stored at 80 oC. Insulin levels were assessed from the serum through a commerciallyavailable ELISA assay (ALPCO Diagnostics, Salam, NH).

Heart Rate
Heart rate was recorded using a Polar heart rate monitor (Lake Success, NY).
Measurements were obtained at minute 8 of the glycogen-depleting trial and the
subsequent exercise trial. Average heart was also recorded for the 20 km time trial
and the final 5 km segment.
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Ratings of Perceived Exertion (RPE)
Ratings of perceived exertion were obtained by having the subjects point to a
corresponding level of exertion on the Borg RPE scale (6-20). The RPE recording
was collected at the 8 minute mark during the glycogen-depleting and subsequent
exercise. The following statement was read to the subjects to explain the RPE
scale: “Please describe your current level of exertion using the following scale.
This level should represent your overall perception of effort, and not localized to
a specific group of muscles, etc. For reference, a 6 would represent your effort
when you are resting or watching TV, while 20 would represent the highest level
of exertion you are capable of producing during exercise”.

Muscle Recovery Variables
Muscle recovery variables included ratings of muscle soreness, mental and
physical energy/fatigue ratings, isometric peak torque (MVC), and serum creatine kinase
(CK). Muscle soreness ratings and mental/physical energy/fatigue ratings were collected
during the following three time points; prior to the glycogen depletion trial (PRE), prior
to the subsequent exercise performance trial (4HrPost) and 24 hours following the
glycogen depletion trial (24HrPost). Serum CK was obtained twice: PRE and 24HrPost.
Peak MVC was assessed five times: PRE, 4HrPost, 24HrPost, as well as immediately
after the glycogen depleting trial and subsequent trial. A visual timeline of the muscle
recovery measurements is provided in Figure 3.1 above.
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Serum Creatine Kinase (CK)
Serum CK was measured as an indirect indicator of muscle damage.
Approximately 5ml of blood were obtained using a venous blood draw from an
antecubital vein prior to exercise and 24-hr post exercise. Using a centrifuge,
whole blood was spun at 7000 rpm to separate serum and stored in a -80

o

C

freezer. Serum CK was analyzed using a Johnson and Johnson Vitro DT6011. The
measurement device was calibrated prior to analyses using a reconstituted
lyophilized calibration standard purchased from the manufacturer.

Muscle Function Test/Isometric peak torque (MVC)
Peak torque of the knee extensors were assessed to determine treatment
differences in muscle function during recovery from exercise. Subjects were
seated in a modified leg extension chair and asked to push as hard as possible
against a shin pad that was connected to a force transducer. Each subject
performed 3 to 6, 5-second repetitions at each time-point. There was a 1 minute
rest between each repetition. MVC was also assessed immediately following both
exercise sessions.

Mental and Physical Energy/Fatigue Ratings
The Mental and Physical State and Trait Energy and Fatigue Scales (MPSTEFS,
O‟Conner, 2004) were used to record ratings of mental and physical energy.
Separate ratings of physical energy, physical fatigue, mental energy and mental
fatigue were obtained using visual analog scales, with potential scores ranging
from 0 to 300 for each rating.
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Muscle Soreness Ratings
During the familiarization trial subjects received instruction on how to utilize the
muscle soreness scale. The following statement was read to the subjects; “please
describe your overall level of muscle soreness that you feel currently while
performing normal daily activities (i.e. walking up or down stairs)”. The soreness
rating used a 100mm visual analog scale; 0 indicated no muscle soreness and 100
indicated impaired movement due to muscle soreness.

Genotyping
Single nucleotide polymorphisms (SNPs) were evaluated in this study to
determine if specific variations in these polymorphisms were associated with variations
in muscle recovery variables, and examine their influence on individual responses to
recovery beverages with protein. The following SNPs were evaluated in this study:
ACTN3 R577X, IGF-II C13790G, IGF-II G17200A, IGF2AS A1364C, and IGF2AS
G11711T. Approximately 4 ml of blood were obtained using a venous blood draw from
an antecubital vein prior to the glycogen depleting exercise during the first trial, and
mixed through inversion. DNA was isolated from each blood sample using the QIAamp®
DNA Blood Mini Kit (Qiagen, CA). Subject identification information was removed for
all DNA samples, which were subsequently shipped to the Research Center for Genetic
Medicine at the Children‟s National Medical Center in Washington D.C. for genotyping.
The following genotype polymorphisms were selected for genotyping based on
their susceptibility to impaired muscle recovery as demonstrated by increased serum CK
levels, strength loss, and muscle soreness following eccentric resistance exercises in prior
research:
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1) IGF-II C13790G (homozygous rare allele found in 18.6% of subjects): 58%
strength loss immediately post-exercise, increased serum CK activity at 7 days
post-exercise (8818 U/l) (Devaney et al., 2007).
2) IGF-II G17200A (homozygous rare allele found in 11.0% of subjects): 60%
strength loss immediately post-exercise, increased CK activity at 7 days postexercise (12261 U/l) (Devaney et al., 2007).
3) IGF2AS A1364C (homozygous wild type found in 36.2% of subjects): 58%
strength loss, 50mm soreness (Devaney et al., 2007).
4) IGF2AS G11711T (homozygous wild type found in 27.8% of subjects): 56%
strength loss, 56mm soreness, increase in blood CK (17,160 U/l) and Mb (659
ng/ml) (Devaney et al., 2007).
In addition, ACTN3 R577X was selected for genotyping due to its potential for
demonstrating improved endurance performance in homozygous rare allele
subjects (Yang et al., 2003; Niemi and Majammaa, 2005; Lucia et al., 2006; and
Eynon et al., 2009).
Genotyping was performed using Applied Biosystem‟s Taqman allele
discrimination assay using standard thermal cycling conditions, with genotypes called by
the 7900HT Real-Time PCR System (Applied Biosystems, CA). For all the SNPs, the
Applied Biosystem assay ID is located in Table 3.1 or if the SNP was not available on
the ABI website, a custom primer set was designed.
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Table 3.1: TaqMan primer sets for SNPs tested.
SNP/
rs number

Forward Primer
or ABI Assay #

IGF-II

C13790G
rs3213221

C__31456535_10

IGF2AS

G11711T
rs7924316

C_29192859_10

IGF-II

G17200A
rs680

TGGACTTGAGT
CCCTGAACCA

IGF2AS

A1364C
rs4244808

C__2981208_10

ACTN3

R577X
rs1815739

C____590093_1_

Gene

Reverse Primer

WT allele
probe
(5' VIC)

MT allele probe
(5' FAM)

GTGCCCACCT
GTGATTTCTG

AGAGAAAA
GAAGGGCC

AAAGAGAAA
AGAAGGACC

Study Treatments
Recovery beverages were consumed immediately following the glycogen
depleting exercise, 2 hours post glycogen depleting exercise, and immediately following
the subsequent exercise performance trial. The study protocols were performed by each
subject on three separate occasions (separated by 7-14 days each). Subjects consumed a
different beverage for each trial. The beverages were provided in a randomlycounterbalanced, double-blinded design. Beverages were refrigerated at 5 oC from 2
hours prior to each trial until immediately prior to being consumed. Subjects were
informed that the beverages consisted of the same amount of fluid with different nutrient
composition, but were not informed the specific composition of the different beverages.
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As this genotype study was conducted as part of a larger recovery beverage study,
it adopted identical protocols that involved the administration of three different
treatments. However, for the purposes of the current genotype study, only data collected
from the carbohydrate-only treatment (CHO) and the high-carbohydrate low-protein
treatment (HCLP) were analyzed.

Carbohydrate-only Beverage (CHO)
The CHO beverage contained 300 kcal, and 75g of carbohydrate, per 625 ml
serving (12% by volume). To provide an isocaloric and isovolumetric (750 ml)
comparison to the other beverage, the CHO beverage was consumed along with
125 ml of water.

High-Carbohydrate, Low-Protein Beverage (HCLP)
Each 250 ml serving of the HCLP beverage contained 300 kcal, 50g carbohydrate,
25g protein, and 0.5g of fat. To provide an isocaloric and isovolumetric (750 ml)
comparison to the other beverage, the HCLP mixture was consumed along with
500 ml of water.

Dietary and Exercise Controls
Subjects were asked not to perform any heavy exercise 48 hours prior to each trial. A 48hour diet and exercise log was completed by each subject preceding each treatment trial,
and participants were instructed to maintain a consistent dietary and exercise habit
between trials. No less than 12 hours prior to the start of the exercise, subjects consumed
their final self-selected meal (dinner the evening prior to testing). After this meal,
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subjects followed the standardized dietary protocol consisting of the following
procedures:
1) No food or beverage intake between dinner and bedtime on the evening prior to the
trial (water was consumed ad libitum).
2) On the morning of the exercise trials, subjects consumed a standardized breakfast two
hours prior to the glycogen-depleting exercise trial. The meal was provided by the
researchers, and consisted of 495-510 kcal, including 90-98g carbohydrate, 8-12g protein
and 4.5-7.5g fat. In order to account for personal tastes, subjects chose from one of 4
meal choices, but the identical meal chosen was repeated across the four trials for each
subject. These dietary restrictions ensured that no differences in nutrient intake occurred
between the intervention periods, other than the treatments provided by the researchers.
3) No nutrients were consumed between the glycogen depleting trial and the subsequent
exercise performance trial, other than the recovery beverages provided by the researchers.
4) No nutrients were consumed for 2 hours following the subsequent exercise
performance trial, other than the recovery beverages provided by the researchers.
5) Subjects resumed their normal diets from 2 hours following the subsequent exercise
performance trial through the 24HrPost measurement period. However, subjects recorded
their dietary intake during this period, and were instructed to maintain similar dietary
habits between the different trials.

Statistical Analyses
SPSS Version 17.0 was used to conduct statistical analyses. One-way Analysis of
Variance (ANOVA) was used to analyze main effects for allele groups for time to
completion for the 20 km and final 5 km during subsequent exercise performance. This
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analysis was repeated for each of the five selected genotypes. Pairwise comparisons were
performed to analyze specific differences in performance variables between allele groups
for each genotype. To analyze genotype effects on markers of muscle recovery (serum
CK levels, peak MVC, mental and physical energy/fatigue and muscle soreness ratings),
repeated measures ANOVAs (RMANOVA) were conducted with „time‟ as the withinsubject factor (pre, post) and „allele group‟ as the between-group factor. Post-hoc
analyses were conducted using pairwise comparisons to analyze specific differences in
change scores for each recovery variable between allele groups for each genotype. For
specific allele groups identified as susceptible to impaired muscle recovery,
RMANOVAs were conducted within the genotype group, with treatment (CHO, HCLP)
and time (pre, post) as within-subject factors.
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INFLUENCE OF GENOTYPE VARIATIONS ON MARKERS OF SKELETAL
MUSCLE RECOVERY FROM HEAVY ENDURANCE EXERCISE, AND ON
RESPONSES TO CARBOHYDRATE-PROTEIN SUPPLEMENTATION

Qingnian Goh, Michael J Saunders, Christopher J Womack, Nicholas D Luden, and
Christopher A Boop

Department of Kinesiology, MSC 2302, James Madison University, Harrisonburg,
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Abstract
Purpose: This study examined the influence of genotype polymorphisms (specifically
ACTN3 R577X, IGF-II C13790C, IGF-II G17200A, IGF2AS A1364C, IGF2AS
G11711T) on markers of skeletal muscle recovery following an acute bout of heavy
endurance exercise, and assessed their role in determining individual responses to
carbohydrate-protein supplementation. Methods: Twelve trained male cyclists completed
repeated cycling trials, each consisting of an initial session of glycogen-depleting
exercise, followed four hours later by a >1 hr time-trial on a computerized cycle
ergometer (VeloTron, Racermate, Inc). Subjects were randomly administered a highcarbohydrate low-protein (HCLP), or carbohydrate-only (CHO) beverage, which was
consumed immediately and 2-hours post glycogen depleting exercise, and immediately
following subsequent exercise. Beverages were isocaloric and isovolumetric. Blood
samples were obtained before the glycogen-depleting exercise of the first trial for
genotyping analysis. Serum creatine kinase (CK), peak muscle function (MVC), mental
and physical energy and fatigue ratings, and muscle soreness ratings were obtained as
markers of muscle recovery at specific time points. Subjects completed these methods for
both treatments in a double-blind protocol. Results: Changes in MVC were significantly
different (P < 0.05) from baseline to 4-hours post glycogen depleting exercise among
genotypes for the ACTN3 R577X, IGF-II C13790C, and IGF2AS A1364C single
nucleotide polymorphisms (SNPs) during the CHO control trial. Changes in
mental/physical energy/fatigue and muscle soreness ratings were significantly different
(P < 0.05) from baseline to 24-hours post glycogen depleting exercise among genotypes
for the ACTN3 R577X and IGF2AS G11711C SNPs during the CHO control trial. These
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variables tended to improve with the HCLP treatment when subjects identified for the
above genotype variations were analyzed, although the improvements were not
statistically significant. Changes in serum CK were not significantly different (P > 0.05)
from baseline to 4-hours post glycogen depleting exercise among genotypes analyzed.
Conclusions: Genotype variations led to significant differences in MVC, physical/mental
energy/fatigue and muscle soreness ratings, which tended to improve with the HCLP
treatment. There were no genotype effects for serum CK.
Key Words: Genotype, Carbohydrate, Protein, Muscle Damage, Recovery
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Introduction
Prolonged high-intensity endurance exercise is associated with depleted glycogen
stores and impairments in markers of muscle recovery. Traditionally, sports beverages
containing water, carbohydrate, and electrolytes have been utilized by endurance athletes
to enhance glycogen replenishment, facilitate muscle recovery, and improve aerobic
performance (Hargreaves et al., 1984; Coyle and Coggan, 1984; Coggan and Coyle 1991;
Coyle, 1992; 1992; Halson, 2004). Recently, the inclusion of protein into carbohydratebased sport beverages to confer additional performance benefits has garnered
considerable attention in the field of exercise science. The inclusion of protein content is
proposed to enhance the rate of muscle recovery, as well as improve subsequent
endurance performance (Saunders et al., 2004; Betts et al., 2007; Berardi et al., 2008;
Rowland et al., 2008; and Skillen et al., 2008).
Current studies examining the efficacy of carbohydrate-protein supplementations
have demonstrated mixed results. Some studies have documented improved performance
in subsequent exercise bouts (Saunders et al., 2004; Betts et al., 2007; Berardi et al.,
2008; Rowland et al., 2008; and Skillen et al., 2008), as well as reductions in markers of
muscle damage and soreness (Saunders et al., 2004; Millard-Stafford et al., 2005;
Romano-Ely et al., 2006; Rowland et al., 2008; and Skillen et al., 2008) with
carbohydrate-protein ingestion. However, other studies have reported no differences in
subsequent exercise performance between carbohydrate and carbohydrate-protein
beverages (Millard-Stafford et al., 2005; Romano-Ely et al., 2006; Betts et al., 2007). In
addition to the variations between studies, there appears to be considerable variations
among individual subjects with respect to the potential efficacy of carbohydrate-protein
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ingestion. For example, Combest et al. (2005) reported that 10 of 14 cyclists performing
exhaustive exercise observed sizable attenuations in post-exercise serum CK levels (ΔCK
= 975 ± 590 U/L) with carbohydrate-protein ingestion, while the remaining four subjects
were non-responders (ΔCK = -10.0 ± 31.6 U/L) to carbohydrate-protein intake.
Furthermore, the carbohydrate-protein „responders‟ experienced improvements in
subsequent exercise performance that were significantly greater than those who were
„non-responders‟.
The variations in findings within current literature suggest that some individuals
are better responders to carbohydrate-protein supplementation than others, although the
mechanism for the variations remains unclear. One possible explanation may lie in the
role of specific genetic polymorphisms. Certain genotypes may predispose individuals to
greater muscle damage following exercise. Hence, such individuals would potentially
respond better to sports recovery beverages containing protein.
Current studies examining genotype associations with muscle damage have
identified specific genotypes associated with increased skeletal muscle damage following
acute exercise: MLCK C37885A (Clarkson et al., 2005), IGF-II C13790G, IGF-II
G17200A, IGF2AS A1364C, IGF2AS G11711T (Devaney et al., 2007), and ACE ID
(Yamin et al., 2007). However, these studies have primarily incorporated eccentric
resistance exercise protocols. The association between genotypes and aerobic exerciseinduced muscle damage is therefore not well understood. Hence, the present study seeks
to determine if genetic polymorphisms (specifically IGF-II C13790G, IGF-II G17200A,
IGF2AS A1364C, IGF2AS G11711T, and ACTN3 R577X) influence muscle
damage/recovery variables following heavy endurance exercise. Differences in
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susceptibility to cycling induced muscle damage could account for the varied responses
to recovery beverage supplementation. The findings may help to determine the likelihood
of individuals responding to recovery beverages containing protein. We hypothesize that
1) variations in genotypes among subjects will lead to significant differences in serum
CK levels, peak muscle function, perceived physical/mental energy/fatigue, and
perceived muscle soreness after acute intense aerobic exercise, and 2) subjects with
genotypes associated with greater increases in the above muscle damage variables will
derive greater reductions in these variables, and significant improvements in time to
completion during a subsequent endurance performance exercise with the ingestion of
high carbohydrate – low protein beverages.
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Methods
Subjects
Fourteen endurance-trained male cyclists (18-45 yrs) were recruited from James
Madison University and the surrounding area. The inclusion criteria included a minimum
of three days a week of cycling for the past 2 months, and a peak aerobic capacity
(VO2peak) greater than 45 ml/kg/min. All subjects received a written consent form that
described the risks and benefits associated with the study. After a description of the
protocols, subjects signed the written consent form. James Madison University
Institutional Review Board approved the experiment design before data collection began.
Procedures
The study design consisted of a pre-testing/screening phase, familiarization trial,
and three treatment trials.
Pre-testing Phase
All potential subjects that met the study criteria completed the following
assessments.
Body Mass and Height
Subjects had their body weight measured to the nearest 0.1kg and height
measured to the nearest 0.5cm.
VO2peak/Wmax
Subjects completed an exercise test to determine their peak oxygen uptake
(VO2peak) and associated power output (Wmax). The test began with subjects riding
a cycle ergometer at a self-selected pace, described as a “comfortable but not easy
pace for an hour long ride.” After subjects selected their initial workload, power
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output was increased by 25 W every 2 minutes until the subject voluntary
requested to stop the test due to fatigue. Peak oxygen uptake and power output
were measured during the test to determine if subjects met entry criteria for the
study, and to establish intensities for subsequent exercise protocols.
Familiarization Trial
All subjects that met the inclusion criteria performed a familiarization trial within
two weeks of the pre-testing assessment. The purpose of the familiarization trial was to
determine if the exercise intensities were appropriate for each subject. The familiarization
trial also allowed subjects to become acclimated to the protocol and establish the
appropriate pace for the time-trial segment. Subjects were tested prior to the treatment
phase in order to alter workloads and to ensure they can complete the treatment trial.
Another purpose of the familiarization trial was to minimize any effects of learning and
the repeated-bout effect, in order to reduce error variance between treatment trials. All
subjects received the CHO recovery beverage during the familiarization trial (described
below). The treatment phases began 7 to 10 days following the familiarization trial. No
blood draws or muscle recovery measures were taken during the familiarization trial.
Treatment Phases
Treatment phases were similar to the familiarization trial with the addition of the
supplementation treatment provided during the trial, and the inclusion of blood draws and
muscle recovery measures. The treatment phase consisted of a glycogen-depleting
exercise, a recovery period and a subsequent time trial.
A visual timeline of events during each of the treatment phase is provided in
Figure 4.1 below.
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Figure 4.1: Timeline for exercise trials and measurements of recovery.
PRE:
MS
MPEF
CK
MVC

Glycogen
Depleting
Trial

Post: 0.5HrPost: 2HrPost: 4HrPost:
MVC
IN
TB
MS
Subsequent
TB
GL
MPEF
Exercise
MVC
Trial

Post: 24HrPost:
MVC MS
TB
MPEF
CK
MVC

4 hours

24 hours
MS=Muscle Soreness, MPEF= Mental/Physical Energy/Fatigue, CK=Creatine Kinase,
MVC= Peak Isometric Torque, TB=Treatment Beverage, IN=Insulin, GL=Gluose

Glycogen-depleting exercise
Subjects performed a steady state warm-up for 10 minute at 60% Wmax.
After the initial 10 minutes of exercise, subjects completed a series of 2 minute
high-intensity intervals. The high-intensity intervals consisted of 2 minutes at
95% Wmax at a cadence of 70 rpm, followed by 2 minutes at 50% W max. Once the
cadence dropped below 70 rpm, the workloads for the high-intensity intervals
were decreased to 85% Wmax, with the cadence remaining at 70 rpm. Once the
cadence dropped below 70 rpm again, the workload for the high-intensity
intervals was further decreased to 75% Wmax. The test was terminated when
subjects failed to maintain a cadence of 70 rpm at this intensity. This protocol was
designed to induce muscle glycogen depletion and moderate fatigue (Kuipers et
al., 1987). Based on similar findings from Karp et al (2006) and Van Loon et al
(2000), the duration of the test was expected to last approximately 50-75 minutes,
with 30-45 minutes of high-intensity intervals. All subjects were permitted to
consume water ad libitum throughout the trial.

56
Recovery Period
Following the glycogen-depleting exercise there was a 4 hour period of
recovery. Subjects consumed 750 ml of a recovery beverage immediately
following this trial and again 2-hours post-exercise (see „treatment beverage‟
below for description).
Subsequent Exercise Performance
After the 4 hour recovery period, subjects performed an endurance
performance trial on a computerized cycle ergometer (VeloTron, Racermate, Inc).
The start of the trial consisted of 20 minutes at a steady-state pace, with intensity
corresponding to 60% Wmax. The purpose of the steady state segment was to
assess steady-state substrate utilization, and to ensure depletion of muscle
glycogen. Following 20 minutes of steady-state exercise, subjects completed a
simulated 20 km time trial. The last 5 km of the course consisted an uphill
segment at 5% elevation. This was included in the protocol to allow an
assessment of late-exercise performance.
All trials were performed at ambient room temperature (70-72 oF). The
subjects were asked to void their bladders prior to all trials. A Windmere fan, set
on „medium‟ speed, was placed 2 meters from the handlebars of the ergometer for
cooling purposes during the trial. Water was provided ad libitum throughout all
trials. Each subject was asked to provide maximal effort and treat each time trial
as a competitive event. For consistency, no verbal encouragement was provided to
the subjects during the time trial. The only feedback subjects received during the
trials regarding performance were distance remaining and distance completed.
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Subjects were given at least one week between trials to ensure complete
recovery. Participants were allotted 14 days to complete a trial in the event of
unrelated illness or unforeseen circumstances, which occurred in four subjects.
Dependent measurements
Subsequent Exercise Performance
Exercise performance was measured using cycling time to completion for the 20
km time trial. Time was also recorded during the final 5km of the course.
Physiological Responses during Steady-State Exercise
Metabolic Measurements
Metabolic measurements were obtained during the glycogen-depleting
trial and during the steady-state segment of the subsequent performance trial
using a SensorMedics Spectra metabolic cart. These measurements were obtained
after 3 minutes of cycling during the glycogen depleting trial (at 60% W max) and
after 3 minutes of cycling during the subsequent performance trial (also at 60%
Wmax). Expired respiratory gases were collected for 5 minutes at each time point.
Average values were calculated using the final 3 minutes of each time period,
following 2 minutes of breathing equilibration. Measurements obtained from the
expired gases included oxygen uptake (VO2), ventilation (VE), and respiratory
exchange ratio (RER).
Blood Glucose and Lactic Acid
Blood samples were obtained immediately prior to exercise, during the
glycogen-depleting trial (at minute 8) and exercise performance trial (at minute
8), and 30 minutes post-exercise. Approximately 0.5 ml of blood was collected
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during each point via a finger-stick. An automated analyzer (YSI 2300 STAT
glucose/lactate analyzer) determined glucose and lactate levels.
Serum Insulin
Thirty minutes after consuming the recovery beverage, 5 ml of blood was
collected using a venous blood draw from an antecubital vein. The blood was
collected in SST clot agent Vacutainer® tubes, centrifuged, and serum stored at 80 oC. Insulin levels were assessed from the serum through a commerciallyavailable ELISA assay (ALPCO Diagnostics, Salam, NH).
Heart Rate
Heart rate was recorded using a Polar heart rate monitor (Lake Success,
NY). Measurements were obtained at minute 8 of the glycogen-depleting trial and
the subsequent exercise trial. Average heart was also recorded for the 20 km time
trial and the final 5 km segment.
Ratings of Perceived Exertion (RPE)
Ratings of perceived exertion were obtained by having the subjects point
to a corresponding level of exertion on the Borg RPE scale (6-20). The RPE
recording was collected at the 8 minute mark during the glycogen-depleting and
subsequent exercise. The following statement was read to the subjects to explain
the RPE scale: “Please describe your current level of exertion using the following
scale. This level should represent your overall perception of effort, and not
localized to a specific group of muscles, etc. For reference, a 6 would represent
your effort when you are resting or watching TV, while 20 would represent the
highest level of exertion you are capable of producing during exercise”.
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Muscle Recovery Variables
Muscle recovery variables included ratings of muscle soreness, mental and
physical energy/fatigue ratings, isometric peak torque (MVC), and serum creatine kinase
(CK). Muscle soreness ratings and mental/physical energy/fatigue ratings were collected
during the following three time points; prior to the glycogen depletion trial (PRE), prior
to the subsequent exercise performance trial (4HrPost) and 24 hours following the
glycogen depletion trial (24HrPost). Serum CK was obtained twice: PRE and 24HrPost.
Peak MVC was assessed five times: PRE, 4HrPost, 24HrPost, as well as immediately
after the glycogen depleting trial and subsequent trial. A visual timeline of the muscle
recovery measurements is provided in Figure 4.1 above.
Serum Creatine Kinase (CK)
Serum CK was measured as an indirect indicator of muscle damage.
Approximately 5ml of blood were obtained using a venous blood draw from an
antecubital vein prior to exercise and 24-hr post exercise. Using a centrifuge,
whole blood was spun at 7000 rpm to separate serum and stored in a -80
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freezer. Serum CK was analyzed using a Johnson and Johnson Vitro DT6011. The
measurement device was calibrated prior to analyses using a reconstituted
lyophilized calibration standard purchased from the manufacturer.
Muscle Function Test/Isometric peak torque (MVC)
Peak torque of the knee extensors were assessed to determine treatment
differences in muscle function during recovery from exercise. Subjects were
seated in a modified leg extension chair and asked to push as hard as possible
against a shin pad that was connected to a force transducer. Each subject
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performed 3 to 6, 5-second repetitions at each time-point. There was a 1 minute
rest between each repetition. MVC was also assessed immediately following both
exercise sessions.
Mental and Physical Energy/Fatigue Ratings
The Mental and Physical State and Trait Energy and Fatigue Scales
(MPSTEFS, O‟Conner, 2004) were used to record ratings of mental and physical
energy. Separate ratings of physical energy, physical fatigue, mental energy and
mental fatigue were obtained using visual analog scales, with potential scores
ranging from 0 to 300 for each rating.
Muscle Soreness Ratings
During the familiarization trial subjects received instruction on how to
utilize the muscle soreness scale. The following statement was read to the
subjects; “please describe your overall level of muscle soreness that you feel
currently while performing normal daily activities (i.e. walking up or down
stairs)”. The soreness rating used a 100mm visual analog scale; 0 indicated no
muscle soreness and 100 indicated impaired movement due to muscle soreness.
Genotypes
Single nucleotide polymorphisms (SNPs) were evaluated in this study to
determine if specific variations in these polymorphisms were associated with variations
in muscle recovery variables, and examine their influence on individual responses to
recovery beverages with protein. The following SNPs were evaluated in this study:
ACTN3 R577X, IGF-II C13790G, IGF-II G17200A, IGF2AS A1364C, and IGF2AS
G11711T. Approximately 4 ml of blood were obtained using a venous blood draw from
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an antecubital vein prior to the glycogen depleting exercise during the first trial, and
mixed through inversion. DNA was isolated from each blood sample using the QIAamp®
DNA Blood Mini Kit (Qiagen, CA). Subject identification information was removed for
all DNA samples, which were subsequently shipped to the Research Center for Genetic
Medicine at the Children‟s National Medical Center in Washington D.C. for genotyping.
The following polymorphisms were selected for genotyping based on their susceptibility
to impaired muscle recovery as demonstrated by increased serum CK levels, strength
loss, and muscle soreness following eccentric resistance exercises in prior research:
1) IGF-II C13790G (homozygous rare allele found in 18.6% of subjects): 58%
strength loss immediately post-exercise, increased serum CK activity at 7 days
post-exercise (8818 U/l) (Devaney et al., 2007).
2) IGF-II G17200A (homozygous rare allele found in 11.0% of subjects): 60%
strength loss immediately post-exercise, increased CK activity at 7 days postexercise (12261 U/l) (Devaney et al., 2007).
3) IGF2AS A1364C (homozygous wild type found in 36.2% of subjects): 58%
strength loss, 50mm soreness (Devaney et al., 2007).
4) IGF2AS G11711T (homozygous wild type found in 27.8% of subjects): 56%
strength loss, 56mm soreness, increase in blood CK (17,160 U/l) and Mb (659
ng/ml) (Devaney et al., 2007).
In addition, ACTN3 R577X was selected for genotyping due to its potential for
demonstrating improved endurance performance in homozygous rare allele
subjects (Yang et al., 2003; Niemi and Majammaa, 2005; Lucia et al., 2006; and
Eynon et al., 2009).
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Genotyping was performed using Applied Biosystem‟s Taqman allele
discrimination assay using standard thermal cycling conditions, with genotypes called by
the 7900HT Real-Time PCR System (Applied Biosystems, CA). For all the SNPs, the
Applied Biosystem assay ID is located in Table 4.1 or if the SNP was not available on
the ABI website than a custom primer set was designed.
Table 4.1: TaqMan primer sets for SNPs tested.
SNP/
rs number

Forward Primer
or ABI Assay #

IGF-II

C13790G
rs3213221

C__31456535_10

IGF2AS

G11711T
rs7924316

C_29192859_10

IGF-II

G17200A
rs680

TGGACTTGAGT
CCCTGAACCA

IGF2AS

A1364C
rs4244808

C__2981208_10

ACTN3

R577X
rs1815739

C____590093_1_

Gene

Reverse Primer

WT allele
probe
(5' VIC)

MT allele probe
(5' FAM)

GTGCCCACCT
GTGATTTCTG

AGAGAAAA
GAAGGGCC

AAAGAGAAA
AGAAGGACC

Study Treatments
Recovery beverages were consumed immediately following the glycogen
depleting exercise, 2 hours post glycogen depleting exercise, and immediately following
the subsequent exercise performance trial. The study protocols were performed by each
subject on three separate occasions (separated by 7-14 days each). Subjects consumed a
different beverage for each trial. The beverages were provided in a randomlycounterbalanced, double-blinded design. Beverages were refrigerated at 5 oC from 2
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hours prior to each trial until immediately prior to being consumed. Subjects were
informed that the beverages consisted of the same amount of fluid with different nutrient
composition, but were not informed the specific composition of the different beverages.
As this genotype study was conducted as part of a larger recovery beverage study,
it adopted identical protocols that involved the administration of three different
treatments. However, for the purposes of the current genotype study, only data collected
from the carbohydrate-only treatment (CHO) and the high-carbohydrate low-protein
treatment (HCLP) were analyzed.
Carbohydrate-only Beverage (CHO)
The CHO beverage contained 300 kcal, and 75g of carbohydrate, per 625
ml serving (12% by volume). To provide an isocaloric and isovolumetric (750 ml)
comparison to the other beverage, the CHO beverage was consumed along with
125 ml of water.
High-Carbohydrate, Low-Protein Beverage (HCLP)
Each 250 ml serving of the HCLP beverage contained 300 kcal, 50g
carbohydrate, 25g protein, and 0.5g of fat. To provide an isocaloric and
isovolumetric (750 ml) comparison to the other beverage, the HCLP mixture was
consumed along with 500 ml of water.
Dietary and Exercise Controls
Subjects were asked not to perform any heavy exercise 48 hours prior to each
trial. A 48-hour diet and exercise log was completed by each subject preceding each
treatment trial, and participants were instructed to maintain a consistent dietary and
exercise habit between trials. No less than 12 hours prior to the start of the exercise,
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subjects consumed their final self-selected meal (dinner the evening prior to testing).
After this meal, subjects followed the standardized dietary protocol consisting of the
following procedures:
1) No food or beverage intake between dinner and bedtime on the evening prior to the
trial (water was consumed ad libitum).
2) On the morning of the exercise trials, subjects consumed a standardized breakfast two
hours prior to the glycogen-depleting exercise trial. The meal was provided by the
researchers, and consisted of 495-510 kcal, including 90-98g carbohydrate, 8-12g protein
and 4.5-7.5g fat. In order to account for personal tastes, subjects chose from one of 4
meal choices, but the identical meal chosen was repeated across the four trials for each
subject. These dietary restrictions ensured that no differences in nutrient intake occurred
between the intervention periods, other than the treatments provided by the researchers.
3) No nutrients were consumed between the glycogen depleting trial and the subsequent
exercise performance trial, other than the recovery beverages provided by the researchers.
4) No nutrients were consumed for 2 hours following the subsequent exercise
performance trial, other than the recovery beverages provided by the researchers.
5) Subjects resumed their normal diets from 2 hours following the subsequent exercise
performance trial through the 24HrPost measurement period. However, subjects recorded
their dietary intake during this period, and were instructed to maintain similar dietary
habits between the different trials.
Statistical Analyses
SPSS Version 17.0 was used to conduct statistical analyses. One-way Analysis of
Variance (ANOVA) was used to analyze main effects for allele groups for time to
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completion for the 20 km and final 5 km during subsequent exercise performance. This
analysis was repeated for each of the five selected genotypes. Pairwise comparisons were
performed to analyze specific differences in performance variables between allele groups
for each genotype. To analyze genotype effects on markers of muscle recovery (serum
CK levels, peak MVC, mental and physical energy/fatigue and muscle soreness ratings),
repeated measures ANOVAs (RMANOVA) were conducted with „time‟ as the withinsubject factor (pre, post) and „allele group‟ as the between-group factor. Post-hoc
analyses were conducted using pairwise comparisons to analyze specific differences in
change scores for each recovery variable between allele groups for each genotype. For
specific allele groups identified as susceptible to impaired muscle recovery,
RMANOVAs were conducted within the genotype group, with treatment (CHO, HCLP)
and time (pre, post) as within-subject factors.
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Results
Demographics
The sample population demographics (age, height, body mass, peak aerobic
capacity, and power output) of the 12 trained male cyclists from which viable DNA could
be extracted are presented in Table 4.2. The average VO2peak of 65.5 mL·kg-1·min-1
represents the 99th percentile for maximal aerobic power based on age-specific norms
prescribed by ACSM (2010).
Table 4.2: Subject Demographics.
Variable

Mean ± SEM

Age (y)
Height (cm)
Weight (kg)
VO2peak (mL·kg-1·min-1)
Wmax (W)

25.5 ± 2.3
177.5 ± 2.2
73.3 ± 2.3
65.5 ± 2.1
351.7 ± 9.8

Genotypes
The genotype distributions of the sample population are presented in Table 4.3.
They include genotype and allele frequencies for ACTN3 SNPs, IGF-II SNPs, and
IGF2AS SNPs. All 12 subjects were homozygous for the wild-type allele of IGF-II ApaI
(G17200A). Hence, analyses of genotype variations on subsequent performance and
markers of recovery were not performed for the IGF-II ApaI G17200A SNP.
Table 4.3: Genotype Distributions and Frequencies.
Gene
ACTN3
IGF-II
IGF-II
IGF2AS
IGF2AS

SNP/(rs number)
R577X (rs1815739)
C13790G (rs3213221)
G17200A (rs680)
A1364C (rs4244808)
G11711T (rs7924316)

Homozygous
Wild Type

Heterozygous

Homozygous
Rare Allele

2 (16.7%, RR)
6 (50%, CC)
12 (100%, GG)
2 (16.7%, AA)
2 (16.7%, GG)

8 (66.7%, RX)
6 (50%, CG)
0 (0%, GA)
5 (41.7%, AC)
7 (58.3%, GT)

2 (16.7%, XX)
0 (0%, GG)
0 (0%, AA)
5 (41.7%, CC)
3 (25.0% TT)

Allele Frequency

Wild type/Rare
0.500/0.500
0.750/0.250
1.000/0.000
0.375/0.625
0.458/0.542
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Subsequent Performance
Performance variables for the subsequent exercise trial (time for 20 km and final
5 km) are presented in Table 4.4. The CHO treatment served as the „control‟ trial. Thus,
all analyses of the influence of genotype on exercise/performance were performed using
data from the CHO trial.
Table 4.4: Subsequent Exercise Performance
– 20 km Time Trial (CHO Treatment).
Variable
Mean ± SEM
Total time to completion
for 20 km (min)

48.5 + 1.5

Time for final 5 km
climb (min)

19.6 + 0.9

Genotype effects on subsequent performance were examined for the CHO
treatment, and the findings are presented in Table 4.5. Subjects homozygous for the wildtype allele of IGF2AS G11711T demonstrated significantly slower time to completion for
the 20 km time trial (P < 0.05), as well as significantly slower time for the final 5 km
climb (P < 0.05). Subjects homozygous for the rare allele of ACTN3 R577X exhibited a
potential trend towards faster ride times in the final 5 km climb (P < 0.10). However, the
difference was not statistically significant (P > 0.05). No significant genotype effects
were observed for any other genotypes on subsequent exercise performance.
Table 4.5: Genotype and Subsequent Exercise Ride Times for CHO treatment.
Variable
20 km time (min)

Genotype/SNP/
(rs number)

Allele/Subjects (n)

Mean ± SEM

IGF2AS G11711T*
(rs7924316)

Homozygous Wild Type (GG, n = 2)**
Heterozygous Wild Type (GT, n = 7)
Homozygous Rare Allele (TT, n = 3)

55.8 + 1.1
47.3 + 1.9
46.5 +1.2

IGF2AS A1364C
(rs4244808)

Homozygous Wild Type (AA, n = 2)
Heterozygous Wild Type (AC, n = 5)
Homozygous Rare-Allele (CC, n = 5)

45.5 + 1.0
49.3 + 1.9
48.9 + 3.9
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5 km climb (min)

IGF-II C13790G
(rs3213221)

Homozygous Wild Type (CC, n = 6)
Heterozygous Wild Type (CG, n = 6)

47.8 + 1.5
49.2 + 2.7

ACTN3 R577X
(rs1815739)

Homozygous Wild Type (RR, n = 2)
Heterozygous Wild Type (RX, n = 8)
Homozygous Rare Allele (XX, n = 2)

50.9 + 6.0
49.2 + 1.5
43.3 + 3.3

IGF2AS G11711T#
(rs7924316)

Homozygous Wild Type (GG, n = 2)**
Heterozygous Wild Type (GT, n = 7)
Homozygous Rare Allele (TT, n = 3)

24.5 + 1.4
18.7 + 1.1
18.7 + 0.7

IGF2AS A1364C
(rs4244808)

Homozygous Wild Type (AA, n = 2)
Heterozygous Wild Type (AC, n = 5)
Homozygous Rare Allele (CC, n = 5)

18.1 + 0.7
19.8 + 1.0
20.1 + 2.1

IGF-II C13790G
(rs3213221)

Homozygous Wild Type (CC, n = 6)
Heterozygous Wild Type (GC, n = 6)

19.5 + 0.8
19.8 + 1.7

ACTN3 R577X
(rs1815739)

Homozygous Wild Type (RR, n = 2)
Heterozygous Wild Type (RX, n = 8)
Homozygous Rare Allele (XX, n = 2)^

22.1 + 3.8
19.9 + 0.8
16.4 + 3.4

* signifies a trend towards a difference (P < 0.10)
#
significantly different from each other (P < 0.05)
** GG times were significantly slower (P < 0.05) than GT and TT
^
signifies a trend towards faster times for XX than RR (P < 0.10)
Based on the above findings in the CHO control trial, the genotypes that were
most likely to be associated with differences in subsequent performance were compared
against the HCLP trial to determine if possible treatment effects between CHO and
HCLP were influenced by genotypes. There were no significant treatment x genotype
interactions for 20 km and final 5 km times (Table 4.6).
Table 4.6: Treatment by Genotype interaction in Subsequent Exercise.
Variable

Genotype/SNP/(rs)

20 km time (min)

IGF2AS G11711T
(rs7924316)

CHO
HCLP

0.980

ACTN3 R577X
(rs1815739)

CHO
HCLP

0.258

IGF2AS G11711T
(rs7924316)

CHO
HCLP

0.941

ACTN3 R577X
(rs1815739)

CHO
HCLP

0.325

5 km climb (min)

Treatment P Value (treatment x genotype interaction)
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Recovery Variables
The markers of muscle recovery following the glycogen depleting exercise were
examined for the CHO treatment, and findings are presented in Table 4.7. There was a
small but significant increase in CK from pre-exercise to 24-hours post exercise (25.0
U/L, P < 0.05). Peak muscle function (MVC) trended towards higher levels 24-hours
post-exercise (P < 0.10), and tended to be lower immediately following glycogen
depleting exercise, but these tendencies were not statistically significant (P > 0.05). There
were significant declines (P < 0.05) in physical energy and mental energy ratings, and
significant increases (P < 0.05) in physical fatigue and mental fatigue ratings from preexercise to 4-hours post exercise. No significant differences were observed in any of the
above ratings from pre-exercise to 24-hours post exercise. Muscle soreness ratings were
significantly elevated (P < 0.05) from pre-exercise to 4-hours post exercise, and from preexercise to 24-hours post exercise.
Table 4.7: Markers of Recovery for CHO Treatment.
Variables
Time Point
Mean ± SEM
Creatine Kinase (U/L)

PreGE
24Post

136.2 + 12.0
161.1 + 17.0*

Muscle Function (MVC)

PreGE
0Post
4Post
24Post

451.1 + 29.9
427.2 + 41.2
445.9 + 24.8
489.5 + 34.7*

Muscle Soreness (mm)

PreGE
4Post
24Post

10.5 + 3.2
36.0 + 5.2*
24.9 + 6.5*

Physical Energy (mm)

PreGE
4Post
24Post

200.3 + 18.2
159.7 + 17.5**
200.4 + 18.6
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Physical Fatigue (mm)

PreGE
4Post
24Post

79.2 + 16.9
148.1 + 19.0*
87.5 + 17.6

Mental Energy (mm)

PreGE
4Post
24Post

194.7 + 20.3
174.6 + 17.8**
200.6 + 19.2

Mental Fatigue (mm)

PreGE
4Post
24Post

94.4 + 19.4
117.5 + 17.6*
89.3 + 20.1

PreGE = pre glycogen depleting exercise, 0Post = 0 hours post glycogen depleting
exercise, 4Post = 4 hours post glycogen depleting exercise, 24Post = 24 hours post
glycogen depleting exercise.
* significant increase from PreGE (P < 0.05)
** significant decline from PreGE (P < 0.05)
The change scores of muscle damage/recovery variables for the CHO treatment
(control trial) were analyzed for genotype effects, and significant findings are presented
in Table 4.8.
Subjects homozygous for the wild-type allele of ACTN3 R577X demonstrated
significantly greater losses in peak MVC from pre to 4-hours post exercise than
heterozygous subjects (P < 0.05). The loss of peak muscle function in the wild-type allele
group also tended to be larger, (but not significantly so) when compared to subjects
homozygous for the rare allele of ACTN3 R577X (P > 0.05). Subjects homozygous for
the rare allele of IGF2AS A1364C demonstrated significantly greater declines in peak
MVC from pre to 4-hours post exercise compared to subjects homozygous for the wild
allele (P < 0.05). When genotyped for IGF-II C13790G, heterozygous subjects
demonstrated significantly greater declines in peak MVC than subjects homozygous for
the wild-type allele (P < 0.05). There were no genotype effects observed for changes in
peak MVC between 0-hour and 24-hours post exercise.
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When genotyped for the IGF2AS G11711T SNP, significant differences (P <
0.05) were observed between genotypes for changes in physical fatigue ratings from preexercise to 4-hours and 24-hours post exercise, and for changes in mental fatigue ratings
from pre-exercise to 24-hours post exercise (see Table 4.8). When genotyped for ACTN3
R577X, changes in physical energy ratings were significantly different between
genotypes from pre-exercise to 4-hours post-exercise (P < 0.05), and a trend towards
significance from pre-exercise to 24-hours post exercise (P < 0.10). There were no
genotype effects observed for changes in physical/mental energy/fatigue ratings at any
time point when subjects were genotyped for IGF-II C13790G and IGF2AS A1364C.
Changes in muscle soreness ratings demonstrated a trend towards significance
from pre-exercise to 24-hours post exercise when genotyped for IGF 2AS G11711T.
There were no significant genotype effects observed for changes in serum CK responses.
Table 4.8: Significant Associations of Genotypes with Markers of Muscle Recovery.
Gene/SNP/(rs number)/
Variable

Time points

ACTN3 R577X
(rs1815739)
Peak Muscle Function

PreGE – 4Post

0.070#

RR (n = 2, 66.3 + 40.4)*
RX (n = 8, -11.9 +10.4)*
XX (n = 2, 12.5 + 38.7)

Physical Energy ratings

PreGE – 4Post

0.019*

RR (n = 2, 78.8 + 15.8)
RX (n = 8, 20.6 +10.0)**
XX (n = 2, 82.5 + 18.5)

Physical Energy ratings

PreGE – 24Post

0.098#

RR (n = 2, 40.5 + 35.0)*#
RX (n = 8, -8.4 + 7.7)*
XX (n = 2, -7.8 + 5.3)#

Mental Energy ratings

PreGE – 24Post

0.126

RR (n = 2, 33.8 + 70.8)*
RX (n = 8, -9.8 + 13.0)*
XX (n = 2, -25.5 + 3.5)

PreGE – 4Post

0.018*

CC (n = 6, -23.5 + 11.6)*
CG (n = 6, 33.8 + 16.6)*

IGF-II C13790G
(rs3213221)
Peak Muscle Function

P Value (genotype
„main effects‟)

Change scores1 + SE
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IGF2AS A1364C
(rs4244808)
Peak Muscle Function

PreGE – 4Post

0.086#

AA (n = 2, -49.7 + 23.6)*
AC (n = 5, 1.6 + 7.8)
CC (n = 5, 30.8 + 23.0)*

IGF2AS G11711T
(rs7924316)
Physical Energy ratings

PreGE – 24Post

0.167

GG (n = 2, 33.0 + 42.5)#
GT (n = 7, -11.8 + 8.2)#
TT (n = 3, 5.0 + 5.0)

Mental Energy ratings

PreGE – 4Post

0.093#

GG (n = 2, 12.8 + 3.8)
GT (n = 7, 34.3 + 8.0)*
TT (n = 3, -8.3 + 22.3)*

Mental Energy ratings

PreGE – 24Post

0.102

GG (n = 2, 52.0 + 57.5)*#
GT (n = 7, -17.9 + 9.1)*
TT (n = 3, -16.7 + 18.8)#

Physical Fatigue ratings

PreGE – 4Post

0.022*

GG (n = 2, 120.5 + 9.0)*
GT (n = 7, 72.0 + 8.9)#
TT (n = 3, 27.3 + 26.9)*#

Physical Fatigue ratings

PreGE – 24Post

0.001*

Mental Fatigue ratings

PreGE – 4Post

0.174

GG (n = 2, 98.3 + 21.3)**
GT (n = 7, -14.8 + 9.6)
TT (n = 3, 2.2 + 4.7)
GG (n = 2, 36.8 + 18.3)
GT (n = 7, 32.9 + 11.1)#
TT (n = 3, -9.0 + 21.9)#

Mental Fatigue ratings

PreGE – 24Post

0.008*

GG (n = 2, 75.3 + 29.3)**
GT (n = 7, -20.8 + 9.0)
TT (n = 3, -22.3 + 21.9)

Muscle Soreness ratings

PreGE – 24Post

0.189

GG (n = 2, 36.8 + 19.8)#
GT (n = 7, 11.9 + 6.9)
TT (n = 3, 5.5 + 3.6)#

PreGE = pre glycogen depleting exercise, 4Post = 4 hours post glycogen depleting
exercise, 24Post = 24 hours post glycogen depleting exercise.
1
Larger change scores in peak muscle function, physical/mental energy ratings represent
greater declines in the respective variables, while larger change scores in physical/mental
fatigue and muscle soreness ratings represent greater increases in those variables.
* significantly different from each other (P < 0.05)
** significantly different than the other two groups (P < 0.05)
#
signifies a trend towards a difference (P < 0.10)
Based on the above findings in the CHO control trial, the genotypes that were
associated with differences in the change scores for muscle recovery variables were
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compared against the HCLP trial to examine whether genotypes influenced potential
treatment effects on recovery measurements. A summary of these treatment x time x
genotype analyses are shown in Table 4.9.
Table 4.9: Treatment x time within Genotypes on markers of muscle recovery.
Gene/SNP/(rs number)/Variable

Time points

Treatment P Value (treatment effect)

ACTN3 R577X
(rs1815739)
Peak Muscle Function

PreGE – 4Post

CHO
HCLP

0.083#

Physical Energy ratings

PreGE – 4Post

CHO
HCLP

0.960

Physical Energy ratings

PreGE – 24Post

CHO
HCLP

0.135

Mental Energy ratings

PreGE – 24Post

CHO
HCLP

0.113

IGF-II C13790G
(rs3213221)
Peak Muscle Function

PreGE – 4Post

CHO
HCLP

0.242

IGF2AS A1364C
(rs4244808)
Peak Muscle Function

PreGE – 4Post

CHO
HCLP

0.083#

IGF2AS G11711T
(rs7924316)
Physical Energy ratings

PreGE – 24Post

CHO
HCLP

0.920

Mental Energy ratings

PreGE – 4Post

CHO
HCLP

0.008*

Mental Energy ratings

PreGE – 24Post

CHO
HCLP

0.333

Physical Fatigue ratings

PreGE – 4Post

CHO
HCLP

0.232

Physical Fatigue ratings

PreGE – 24Post

CHO
HCLP

0.136

Mental Fatigue ratings

PreGE – 4Post

CHO
HCLP

0.146
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Mental Fatigue ratings

PreGE – 24Post

CHO
HCLP

0.123

Muscle Soreness ratings

PreGE – 24Post

CHO
HCLP

0.031*

* significantly different from each other (P < 0.05)
#

signifies a trend towards a difference (P < 0.10)
Treatment x time analyses were performed within the genotype groups that were

identified to be susceptible to impaired muscle recovery following heavy endurance
exercise (Table 4.10). Small sample-sizes (n = 2 – 6) precluded any strong likelihood to
observe statistically significant differences between treatments. However, visual analysis
of the means showed that markers of muscle recovery improved with the HCLP treatment
in nine of the fourteen variables examined (Table 4.10). Three variables were identical
between treatments and two variables showed worsened scores with the HCLP treatment.
Table 4.10: Treatment x Time Effects on markers of muscle recovery within
“susceptible” Genotype groups.
Gene/SNP/(rs number)/
Allele/Variable
ACTN3 R577X
(rs1815739)
Homozygous Wild-Type (RR, n = 2)
Peak Muscle Function

Treatment Time points Mean + SEM

CHO
HCLP

Physical Energy ratings

CHO
HCLP

Physical Energy ratings

CHO
HCLP

Mental Energy ratings

CHO
HCLP

P Value (treatment
x time effect)

PreGE
4Post
PreGE
4Post

588.5 + 165.7
522.2 + 125.3
565.3 + 119.1
603.2 + 161.9

0.429*

PreGE
4Post
PreGE
4Post

180.5 + 84.5
101.8 + 68.8
181.0 + 105.0
105.0 + 27.0

0.972

PreGE
24Post
PreGE
24Post

180.5 + 84.5
140.0 + 49.5
181.0 + 105.0
156.8 + 93.3

0.612*

PreGE
24Post
PreGE
24Post

149.8 + 72.3
100.3 + 12.3
171.0 + 68.0
178.3 + 82.8

0.587*
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IGF-II C13790G
(rs3213221)
Heterozygous Wild-Type (CG, n = 6)
Peak Muscle Function

CHO
HCLP

IGF2AS A1364C
(rs4244808)
Homozygous Rare Allele (CC, n = 2)
Peak Muscle Function

CHO
HCLP

IGF2AS G11711T
(rs7924316)
Homozygous Wild-Type (GG, n = 2)
Physical Energy ratings

CHO
HCLP

Mental Energy ratings

CHO
HCLP

Mental Energy ratings

CHO
HCLP

Physical Fatigue ratings

CHO
HCLP

PreGE
4Post
PreGE
4Post

484.4 + 56.2
450.6 + 43.4
483.0 + 40.3
476.7 + 58.5

0.449*

PreGE
4Post
PreGE
4Post

484.6 + 67.6
453.8 + 49.4
522.8 + 51.9
527.7 + 65.6

0.420*

PreGE
24Post
PreGE
24Post

193.8 + 71.3
160.8 + 28.8
214.0 + 72.0
169.3 + 80.8

0.857

PreGE
4Post
PreGE
4Post

172.3 + 49.8
159.5 + 46.0
186.5 + 52.5
92.3 + 2.8

0.327#

PreGE
24Post
PreGE
24Post

172.3 + 49.8
120.3 + 7.8
186.5 + 52.5
179.0 + 82.0

0.699*

PreGE
4Post
PreGE
4Post

52.5 + 31.5
173.0 + 22.5
56.0 + 45.0
175.0 + 23.0

0.984

Physical Fatigue ratings

CHO
HCLP

PreGE
24Post
PreGE
24Post

52.5 + 31.5
150.8 + 10.3
56 + 45.0
124.5 + 51.5

0.478*

Mental Fatigue ratings

CHO

PreGE
4Post
PreGE
4Post

94.5 + 2.5
131.3 + 20.8
76.5 + 16.5
177.3 + 46.8

0.576#

HCLP
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Mental Fatigue ratings

CHO
HCLP

Muscle Soreness ratings

CHO
HCLP

* improvements observed with HCLP treatment
#

declines observed with HCLP treatment

PreGE
24Post
PreGE
24Post

94.5 + 2.5
169.8 + 26.8
76.5 + 16.5
84.8 + 58.8

0.521*

PreGE
24Post
PreGE
24Post

17.5 + 15.5
54.3 + 4.3
14.0 + 11.0
24.5 + 5.0

0.194*
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Discussion
The genotype distributions and allele frequencies of the ACTN3 R577X, IGF-II
C13790G, and IGF2AS G11711T SNPs in the sample population are similar to those
reported by Clarkson et al. (2005) and Devaney et al. (2007). The population frequency
of the IGF-II G17200A and IGF2AS A1364C SNPs differed from the findings of
Devaney et al. In our study, subjects were exclusively homozygous for the wild-type
allele of IGF-II G17200A, and there were more subjects homozygous for the rare allele
than the wild-type allele of IGF2AS A1364C. These discrepancies could be attributed to
a small sample size (n = 12) and possibly an all-Caucasian sample in the present study,
compared to a larger and more diverse sample population analyzed by Devaney et al (J M
Devaney, personal communication, April 2, 2010).
The most important findings in this study were that the ACTN3 R577X, IGF-II
C13790C, IGF2AS A1364C, and IGF2AS G11711T SNPs were associated with
alterations in markers of muscle recovery following heavy endurance exercise. In
addition, ACTN3 R577X and IGF2AS G11711T SNPs were observed to be potentially
associated with subsequent aerobic exercise performance.
Subjects homozygous for the wild-type allele of IGF2AS G11711T SNP had
significantly slower times to completion during subsequent exercise for the 20 km (55.8
+ 1.1 min) and final 5 km (24.5 + 1.4 min) in the CHO control trial than heterozygous or
homozygous rare allele subjects. This could be attributed to a greater impairment of
muscle recovery, as demonstrated by a substantial increase in physical fatigue ratings
(120.5 + 9.0 mm), and an increase in mental fatigue ratings (36.8 + 18.3 mm) from pre to
4-hours post glycogen depleting exercise within this allele group. These results agreed

78
with the findings of Devaney et al., who reported impaired muscle function following
eccentric resistance exercise in homozygous wild-type subjects (2007). Alternatively, this
genotype could have influenced the general performance capacity of the individual
subjects, rather than recovery per se. This possibility is supported by the observation that
homozygous wild-type subjects completed only 42.3 + 7.3 min in their glycogen
depleting trial, compared to >60 min in the other genotype groups.
Subjects homozygous for the rare allele of ACTN3 R577X trended towards faster
ride times for the final 5 km (16.4 + 3.4 min) in the CHO control trial than heterozygous
and homozygous wild-type subjects (P < 0.10). Faster ride times were also recorded for
rare allele subjects during the 20 km ride (43.3 + 3.3 min), but they were not significantly
different (P > 0.05) than the other allele groups. The expression of ACTN3 has been
discovered to be limited to a subset of Type II fast twitch muscle fibers (North and
Beggs, 1996). The 577X polymorphism results in deficiency of the alpha-actinin-3
protein, and this mutation may manifest more commonly in certain populations. Findings
from Yang et al. (2003), Niemi and Majammaa (2005), Lucia et al. (2006), and Eynon et
al. (2009) revealed a higher frequency of the XX (ACTN3 null) rare allele in endurance
athletes (distance runners and elite cyclists), compared to a higher frequency of the RR
allele in elite sprinters. In addition, Vincent et al. observed significantly greater
distributions of Type IIx fibers in RR than XX-allele subjects (2007). These findings
suggest that the R allele may be more associated with anaerobic sprint performance,
whereas the X allele may be more associated with endurance performance. Hence, while
the time to completion may not be significantly different in our study, the results agreed
with previous studies as faster riding times were observed in XX-allele subjects. This also
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supports our previous statement that the genotype may be influencing general
performance capacity more than „recovery‟.
There were no significant changes in CK responses from pre-exercise to 24-hours
post exercise during the CHO control trial in all genotype groups. A possible explanation
for the lack of significant CK elevations with exercise may be attributed to the training
status of the sample population in this study. The average VO2peak of the 12 subjects in
this study was 65.5 mL·kg-1·min-1, which represents the 99th percentile for maximal
aerobic power based on age-specific norms prescribed by ACSM (2010). This was higher
than the VO2peak/max values observed in prior cycling studies conducted by our laboratory
(Saunders, Kane, and Todd, 2004; Romano-Ely et al., 2006; Saunders, Luden, and
Herrick, 2007; Valentine et al., 2008; and Saunders et al., 2009). The higher maximal
aerobic capacity observed in our present study may indicate that the intensity/workload
prescribed in the glycogen depleting exercise did not provide a stimulus challenging
enough to impose substantial increases in muscle damage, as measured by serum CK
responses. Consequently, this impaired our ability to discern the potential effects of
genotype on variations in CK responses post-exercise.
Changes in peak muscle function (MVC) measured 4-hours post exercise were
observed to be more sensitive to significant changes from pre-glycogen exercise levels
compared to 24-hours post exercise, when they had returned to pre-exercise levels.
Subjects homozygous for the wild-type allele of ACTN3 R577X sustained significantly
greater strength losses (66.3 + 40.4 N) 4-hours post exercise than rare allele subjects. The
increased loss of strength in homozygous wild-type subjects may contribute to slower
riding times than rare allele subjects, as described above. Conversely, observed strength
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losses in this study differed from the findings of Clarkson et al. (2005), who reported that
the ACTN3 R577X SNP was not associated with changes in strength post exercise.
However, Clarkson et al. utilized an eccentric resistance exercise protocol to elicit muscle
damage, and did not assess strength changes at 4-hours post exercise. One possible factor
for the increased strength loss in homozygous wild-type subjects may be attributed to
fiber type characteristics. Vincent et al. (2007) observed that the RR-allele is associated
with increased distribution of Type IIx fibers (5%, P < 0.05). An increased recruitment of
these fibers during the high-intensity interval segments of the glycogen depleting
protocol may potentially elicit greater disruption to the sarcomere structures (e.g. Z-line
streaming), which would lead to greater declines in MVC 4-hours post exercise.
However, this development seems unlikely in our study, as it should have also resulted in
increased CK levels.
Subjects heterozygous for the IGF-II C13790G SNP demonstrated significantly
greater declines in peak MVC (33.8 + 16.6 N) than subjects homozygous for the wildtype allele. Although our sample size was not large enough to include subjects
homozygous for the rare allele, the results agreed with findings from Devaney et al.
(2007), who found that the homozygous rare-allele subjects experienced significantly
greater strength losses (58%) than homozygous wild-type subjects. This would indicate
that the G allele may be associated with an increased loss of strength with exertional
muscle damage, regardless of whether resistance or aerobic exercise is performed.
When genotyped for the IGF2AS A1364C SNP, homozygous rare allele subjects
demonstrated significantly greater strength losses (30.8 + 23.0 N) than homozygous wildtype allele subjects. These results differ from those of Devaney et al., who reported the
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greatest strength loss (58%) in homozygous wild-type subjects. The differences may be
attributed to our smaller population sample, compared to a much larger population
sample (n = 73) assessed by Devaney et al. Our population was also exclusive to
Caucasian males, whereas Devaney et al. did not classify their findings according to
ancestry. A study conducted by the Devine Laboratory at the University of Maryland
School of Medicine (Institute for Genome Sciences) as part of the International HapMap
project examined the genotype distribution of 118 Utah residents of Northern and
Western European ancestry (NCBI, 2003). When genotyped for the IGF2AS A1364C
SNP, it was observed that 32.2% of the subjects were homozygous for the wild-type
allele, 44.1% were heterozygous, and 23.7% were homozygous for the rare allele. The
genotype distributions for this SNP were more closely matched by those reported in
Devaney et al. (36.2%, 44.7%, 19.1%) than findings in the present study (16.7%, 41.7%,
41.7%) even though Devaney et al. did not genotype the sample population according to
ancestry. This may indicate that ancestral variations in this genotype do not significantly
impact the variables assessed in the present study. Hence, the differences in strength
losses observed between the present study and those of Devaney et al. may be more
related to the discrepancies in sample size.
Physical and mental energy and fatigue ratings, and muscle soreness ratings, were
observed to be most sensitive to significant changes from pre-glycogen depleting exercise
to 24-hours post exercise in the CHO control trial, although significant changes were
observed in several ratings 4-hours post exercise as well. Subjects homozygous for the
ACTN R577X wild-type allele reported significantly larger declines in physical and
mental energy ratings (40.5 + 35.0 mm, 33.8 + 70.8 mm) 24 hours after their initial
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exercise. This coincided with the above finding of decreased peak muscle function in
these subjects, which would indicate that the RR wild-type allele of the ACTN3 R577X
SNP may be more associated with impaired recovery from heavy endurance exercise.
The IGF2AS G11711T SNP appeared to have the greatest influence on
physical/mental energy/fatigue and muscle soreness ratings among the genotypes
analyzed. In particular, 24-hours after the initial exercise, subjects homozygous for the
wild-type allele reported significantly larger declines in physical and mental energy
ratings (33.0 + 42.5 mm, 52.0 + 57.5 mm), in conjunction with substantially larger
elevations in physical and mental fatigue ratings (98.3 + 21.3 mm, 75.3 + 29.3 mm), as
well as greater increases in muscle soreness ratings (36.8 + 19.8 mm). In addition, as
discussed above, homozygous wild-type subjects reported larger increases in physical
and mental fatigue ratings 4-hours post glycogen depleting exercise, which might have
contributed to their slower ride times during the subsequent exercise for the 20 km and
final 5 km. These findings would suggest that the GG wild-type allele of the IGF2AS
G11711T SNP may be more associated with impaired recovery from heavy endurance
exercise, which would agree with the increased strength loss (58%) and soreness (56 mm)
reported by Devaney et al. (2007).
A secondary purpose of the present study was to determine if potentially
susceptible genotype groups (i.e. those expressing impaired muscle recovery) derived
greater benefits from carbohydrate and protein ingestion, which have been shown in
some studies to attenuate post-exercise disruptions in CK, muscle function, and muscle
soreness. Treatment x time effects were examined for the alleles identified to be
susceptible to impaired recovery, and several tendencies were observed for markers of
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muscle recovery to be improved with the HCLP treatment. Peak muscle function was
higher 4-hours post exercise during the HCLP trial than the CHO trial in all genotypes
analyzed. Furthermore, six out of seven 24-hours post exercise ratings were found to be
improved with the HCLP trial, with only the physical energy rating showing no changes
between treatments in subjects homozygous for the IGF2AS G11711T wild-type allele.
However, none of these treatment x time interactions were statistically significant,
perhaps due to the small sample size for the genotype groups (n = 2-6). Hence, although
our findings were preliminary in nature, they warrant further investigations with larger
population samples to better understand the influence of genotype variations on response
to carbohydrate-protein supplementation.
To summarize our findings, when assessing subsequent performance variables,
we observed that the homozygous XX rare allele for ACTN3 R577X to be associated
with improved performance during subsequent exercise, whereas the homozygous GG
wild-type allele for IGF2AS G11711T was associated with slower riding times to
completion. With regards to recovery variables, we observed that the homozygous RR
wild-type allele for ACTN3 R577X, the homozygous GG rare allele for IGF-II C13790G,
the homozygous CC rare allele for IGF2AS A1364C, and the homozygous wild-type GG
allele for IGF2AS G11711T to be most susceptible to impaired recovery following heavy
endurance exercise. Peak muscle function appeared to be most sensitive to significant
changes from pre to 4-hours post glycogen depleting exercise, whereas physical/mental
energy/fatigue and muscle soreness ratings appeared to be most sensitive to significant
changes from pre to 24-hours post exercise. When assessing the treatment x time effects

84
within genotypes, the HCLP treatment demonstrated a potential tendency to improve
markers of muscle recovery in „susceptible‟ genotype groups.
We recommend that future studies recruit larger population samples to analyze
treatment differences in subjects identified with the specific allele distributions listed
above, and to incorporate an initial exercise protocol that elicits greater muscle damage.

85

References
American College of Sports Medicine. ACSM’s Guidelines for Exercise Testing and
Prescription. 8th Ed. Baltimore: Lippincott Williams & Wilkins, 2010
Berardi JM, Noreen EE, and Lemon PW. Recovery from a cycling time trial is enhanced
with
carbohydrate-protein
supplementation
vs.
isoenergetic
carbohydrate
supplementation. Journal of the International Society of Sports Nutrition 5:24, 2008.
Betts JA, Williams C, Duffy K, and Gunner F. The influence of carbohydrate and protein
ingestion during recovery from prolonged exercise on subsequent endurance
performance. Journal of Sports Sciences 25 (13): 1449 – 1460, 2007
Clarkson PM, Hoffman EP, Zambraski E, Gordish-Dressman H, Kearns A, Hubal M,
Harmon B, and Devaney JM. ACTN3 and MLCK genotype associations with exertional
muscle damage. Journal of Applied Physiology 99 (2): 564 – 569, 2005
Coggan AR and Coyle EF. Carbohydrate ingestion during prolonged exercise: effects on
metabolism and performance. Exercise Sports Science Reviews 19: 1 – 40, 1991
Combest T, Saunders MJ, Kane MD, and Todd MK. Attenuated CPK Following
Carbohydrate/Protein Intervention Improves Subsequent Performance. Medicine and
Science in Sports and Exercise 37 (5): S43, 2005 [Abstract]
Coyle EF. Carbohydrate feeding during exercise. International Journal of Sports
Medicine 13 (Suppl 1): S126 – 128, 1992
Coyle EF. Carbohydrate supplementation during exercise. Journal of Nutrition 122 (3
Suppl): 788 – 795, 1992
Coyle EF and Coggan AR. Effectiveness of carbohydrate feeding in delaying fatigue
during prolonged exercise. Sports Medicine 1: 446 – 458, 1984
Devaney JM, Hoffman EP, Gordish-Dressman H, Kearns A, Zambraski E, and Clarkson
PM. IGF-II gene region polymorphisms related to exertional muscle damage. Journal of
Applied Physiology 102 (5): 1815 – 1823, 2007
Eynon N, Duarte JA, Oliveira J, Sagiv M, Yamin C, Meckel Y, Sagiv M, and
Goldhammer E. ACTN3 R577X polymorphism and Israeli top-level athletes.
International Journal of Sports Medicine 30 (9): 695 – 698, 2009
Halson SL, Lancaster GI, Achten J, Gleeson M, and Jeukendrup AE. Effects of
carbohydrate supplementation on performance and carbohydrate oxidation after
intensified cycling training. Journal of Applied Physiology 97 (4): 1245 – 1253, 2004

86

Hargreaves M, Costill DL, Coggan A, Fink WJ, and Nishibata I. Effect of carbohydrate
feedings on muscle glycogen utilization and exercise performance. Medicine & Science
in Sports & Exercise 16 (3): 219 – 222, 1984
Karp JR, Johnston JD, Tecklenburg S, Mickleborough TD, Fly AD, and Stager JM.
Chocolate milk as a post-exercise recovery aid. International Journal of Sport Nutrition
and Exercise Metabolism 16 (1): 78 – 91, 2006
Kuipers H, Keizer HA, Brouns F, and Saris WH. Carbohydrate feeding and glycogen
synthesis during exercise in man. Pflügers Archiv European Journal of Physiology 410
(6): 652 – 656, 1987
Lucia A, Gómez-Gallego F, Santiago C, Bandrés F, Earnest C, Rabadán M, Alonso JM,
Hoyos J, Córdova A, Villa G, and Foster C. ACTN3 genotype in professional endurance
cyclists. International Journal of Sports Medicine 27 (11): 880 – 884, 2006
Martínez-Lagunas V, Ding Z, Bernard JR, Wang B, and Ivy JL. Added protein maintains
efficacy of a low-carbohydrate sports drink. Journal of Strength and Conditioning
Research 24 (1): 48 – 59, 2010
Millard-Stafford M, Warren GL, Thomas LM, Doyle JA, Snow T, and Hitchcock K.
Recovery from run training: efficacy of a carbohydrate-protein beverage? International
Journal of Sport Nutrition and Exercise Metabolism 15 (6): 610 – 624, 2005
NCBI. Single Nucleotide Polymorphisms – Reference SNP (refSNP) Cluster Report:
rs4244808~http://www.ncbi.nlm.nih.gov/projects/SNP/snp_ref.cgi?rs=4244808. (16 Mar,
2003).
Niemi AK and Majamaa K. Mitochondrial DNA and ACTN3 genotypes in Finnish elite
endurance and sprint athletes. European Journal of Human Genetics 13 (8): 965 – 969,
2005
North KN and Beggs AH. Deficiency of a skeletal muscle isoform of alpha-actinin
(alpha-actinin-3) in merosin-positive congenital muscular dystrophy. Neuromuscular
Disorders 6 (4): 229 – 235, 1996
Osterberg KL, Zachwieja JJ, and Smith JW. Carbohydrate and carbohydrate + protein for
cycling time-trial performance. Journal of Sports Sciences 26 (3): 227 – 233, 2008
Romano-Ely BC, Todd MK, Saunders MJ, and St Laurent TG. Effects of an isocaloric
carbohydrate-protein-antioxidant drink on cycling performance. Medicine & Science in
Sports & Exercise 38 (9): 1608 – 1616, 2006
Rowlands DS, Rössler K, Thorp RM, Graham DF, Timmons BW, Stannard SR, and
Tarnopolsky MA. Effect of dietary protein content during recovery from high-intensity

87
cycling on subsequent performance and markers of stress, inflammation, and muscle
damage in well-trained men. Applied Physiology, Nutrition, and Metabolism 33 (1): 39 –
51, 2008
Saunders MJ, Kane MD, and Todd MK. Effects of a carbohydrate-protein beverage on
cycling endurance and muscle damage. Medicine and Science in Sports and Exercise 36
(7): 1233 – 1238, 2004
Saunders MJ, Luden ND, and Herrick JE. Consumption of an oral carbohydrate-protein
gel improves cycling endurance and prevents postexercise muscle damage. Journal of
Strength and Conditioning Research 21 (3): 678 – 684, 2007
Saunders MJ, Moore RW, Kies AK, Luden ND, and Pratt CA: Carbohydrate and protein
hydrolysate coingestions improvement of late-exercise time-trial performance.
International Journal of Sport Nutrition and Exercise Metabolism 19 (2): 136 – 149,
2009
Skillen RA, Testa M, Applegate EA, Heiden EA, Fascetti AJ, and Casazza GA. Effects of
an amino acid carbohydrate drink on exercise performance after consecutive-day exercise
bouts. International Journal of Sport Nutrition and Exercise Metabolism 18 (5): 473 –
492, 2008
Valentine RJ, Saunders MJ, Todd MK, and St Laurent TG. Influence of carbohydrateprotein beverage on cycling endurance and indices of muscle disruption. International
Journal of Sport Nutrition and Exercise Metabolism 18 (4): 363 – 378, 2008
Van Essen M and Gibala MJ. Failure of protein to improve time trial performance when
added to a sports drink. Medicine and Science in Sports and Exercise 38 (8): 1476 –
1483, 2006
Van Loon LJ, Saris WHM, Kruijshoop M, and Wagenmakers AJM. Maximizing
postexercise muscle glycogen synthesis: carbohydrate supplementation and the
application of amino acid or protein hydrolysate mixtures. American Journal of Clinical
Nutrition 72: 106 – 111, 2000
Vincent B, De Bock K, Ramaekers M, Van den Eede E, Van Leemputte M, Hespel P, and
Thomis MA. ACTN3 (R577X) genotype is associated with fiber type distribution.
Physiological Genomics 32 (1): 58 – 63, 2007
Yamin C, Amir O, Sagiv M, Attias E, Meckel Y, Eynon N, Sagiv M, and Amir RE. ACE
ID genotype affects blood creatine kinase response to eccentric exercise. Journal of
Applied Physiology 103 (6): 2057 – 2061, 2007
Yang N, MacArthur DG, Gulbin JP, Hahn AG, Beggs AH, Easteal S, and North K.
ACTN3 genotype is associated with human elite athletic performance. American Journal
of Human Genetics 73 (3): 627 – 631, 2003

Chapter V
Conclusions

1)

Genotype variations among subjects led to significant differences in peak muscle
function (MVC) changes from resting levels to 4-hours following acute heavy
endurance exercise.

2)

Genotypes variations among subjects led to significant differences in changes for
physical and mental energy and fatigue ratings, as well as changes in muscle soreness
ratings, from resting levels to 24-hours following acute heavy endurance exercise.

3)

Subjects with genotypes that were associated with greater increases in the above
markers of muscle recovery tended to improve these variables with the ingestion of
high carbohydrate – low protein beverages, although the differences were not
statistically significant.

89
Appendix I
James Madison University
School of Kinesiology and Recreation Studies
Consent for Investigative Procedure
I, ______________________, herby agree on _____________ (date) to participate in the
research project conducted by Dr. Michael Saunders, Dr. Nick Luden, Chris Boop and Qing Goh
from James Madison University entitled “Altered carbohydrate and protein content in sports
beverages: Influence on recovery from heavy endurance exercise”.
Purpose
The purpose of this study is to determine if the ingredients in sports beverages affects short-term
recovery from heavy cycling exercise. The proposed study will take approximately 4-5 weeks to
complete. It will consist of a pretest physical assessment, a familiarization trial, and three
treatment beverage/recovery trials (detailed below). The study will take place September, 2009 –
August 2010, in the Human Performance Laboratory in Godwin Hall, Room 209, JMU.
Subject Responsibility
I understand that I will undergo the following testing in the study:
Pre-testing Phase:
Before any physical evaluation is given, I will complete pre-screening forms to insure that I meet
the study criteria, and that I do not have any risk factors for heavy exercise. In the process of
filling out these forms, I will share information regarding my general health and lifestyle with the
researchers. In addition, I will notify the researchers if I have any known allergies to milk or milkproducts. If I meet the criteria for the study, I will complete an assessment of my
cardiorespiratory fitness and body mass. During this assessment, I will perform an exercise test
to determine my maximal oxygen uptake (VO2max). To do this, I will ride a stationary cycle at an
initial workload that is „fairly easy‟. Workload will be increased every few minutes during the test.
I will be encouraged to continue to cycle until I request to stop due to fatigue or am unable to
continue at a cadence >60 rpm. In order to be included as a participant in the study, I must
achieve a VO2max of >45 ml/kg/min. If I meet these criteria, I will complete a familiarization trial, in
which I perform the procedures described below (in Treatment Phases), without any of the testing
that follows the Subsequent Exercise Performance Test.
Treatment Beverage/Recovery Trials
Following pre-testing, I will perform three exercise/recovery phases. Each of these phases will be
identical, with the exception that a different sports beverage will be utilized during each phase.
Approximately 7-14 days will be provided between each treatment phase.

Exercise/Recovery Phases:
Two hours following a standardized meal (see below), I will report to the laboratory to
complete an exercise session on an exercise cycle, consisting of high-intensity aerobic
intervals. This trial will take approximately 1-2 hours to complete. Four hours following the
initial exercise session, I will perform a Subsequent Exercise Performance Test, consisting of
30-min of moderate-intensity cycling followed by a 20 km time-trial, which will take
approximately 40-45 min to complete. I will be encouraged to treat the trial as a competitive
event, and give my best effort throughout the trials. Twenty-four hours after the trial, I will
return to the laboratory to assess markers of muscle damage and recovery.
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I will complete the following procedures at various time-points during the protocol:
Blood draws – Blood will be collected immediately prior to exercise, between the two exercise
sessions, and 24-hours following exercise. Each of these blood draws will be conducted by
inserting a needle into a vein in the upper forearm. During each sample, small amounts of
blood (~5-10 ml) will be obtained, and utilized to measure either insulin or markers of muscle
damage. Some blood from these collections will also be used to assess genotype variations
that may be related to muscle damage. In addition, blood glucose and lactate will be
assessed once during each during exercise session, using a finger-stick technique, in which
a very small amount of blood (~0.5 ml) is obtained. The total amount of blood obtained
during each trial period is approximately 20 ml, (60 ml over the course of the entire trial).
This total amount is less than 1/5 of a can of soda, or 15% of the amount given when
donating blood in a single session (approximately 1 pint, or 473 ml). The indicated frequency
of blood draws represents the bare minimum number required to be able to assess the
dependent measurements indicated within this protocol (muscle damage, insulin, glucose &
lactate). Study participants should refrain from donating blood during the study period.
Measurements During Exercise:
At one time-point during the high-intensity aerobic intervals, and also once during the
Subsequent Exercise Performance Test, the following measurements will be obtained:
Metabolic Measurements. I will have metabolic measurements, such as oxygen uptake,
ventilation, etc. measured using a SensorMedics metabolic cart. To do this, I will breathe
through a mouthpiece/breathing apparatus that collects my expired breath for
approximately 5 minutes. The mouthpiece/breathing apparatus will NOT be worn during
exercise other than at the indicated time-point.
Ratings of Perceived Exertion –I will provide subjective ratings of my exertion level. I will
do this by pointing to my corresponding level of exertion (rated numerically from 6-20) on
a Borg RPE scale.
Heart Rate. I will have my heart rate measured using a Polar heart rate monitor that is
worn around my chest throughout each exercise session.
Measurements Before and After Exercise:
Muscle Soreness and Fatigue Ratings. I will provide muscle soreness and fatigue ratings
using a series of 100mm visual analog scales, with 0 indicating (i.e.) no muscle soreness
and 100 indicating impaired movement due to muscle soreness. These ratings will be
obtained immediately prior to the first exercise session (high-intensity aerobic intervals),
immediately prior to the second exercise session (Subsequent Exercise Performance
Test), and 24-hours following the first exercise session.
Muscle Function - I will perform a maximal strength test of my quadriceps at the following
time-points: prior to the first exercise session (high-intensity aerobic intervals), following
the first exercise session, prior to the second exercise session (Subsequent Exercise
Performance Test), following the second exercise session, and 24-hours following the
first exercise session.
During this test, I will be seated in a modified chair, and asked to push as hard as
possible against a shin pad that will be connected to a force transducer for about 5
repetitions with a minute rest in between.
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Sports Beverages and Dietary Controls: I will consume 625 ml of a sports beverage at the
following time-points: a) immediately following the first exercise session (high-intensity aerobic
intervals), b) two-hours following the first exercise session, and c) immediately following the
second exercise session (Subsequent Exercise Performance Test). I will perform the study
protocols on three occasions (separated by 7-14 days each), using a different sports beverage on
each occasion. Treatments will contain the same amount of fluid but will contain differing
amounts of other nutrients (carbohydrates, fat and/or protein). The specific composition of
beverages utilized in the study will not be revealed to me during the study. However, I may
request this information upon completion of the study.
Two hours prior to each trial, I will receive and consume a small standardized meal. I may select
the specific food type from one of three choices, but the specific foods consumed during this
period will be replicated across each of the three treatment periods. In addition, I will be
encouraged to maintain consistent dietary and exercise habits across the duration of the two
treatment periods. I will complete a dietary log of all foods consumed during the days prior and
following each of the exercise sessions. In addition, I will record the type, amount and intensity
of all exercise performed during these same time periods. I will also refrain from heavy exercise
for 48-hours prior to each exercise test, and will not exercise between the exercise tests and
follow-up testing (24 hours).
Risks:
Participants are expected to be honest about disclosing all known risk factors to the researcher.
There are no known risk factors associated with sports beverage consumption. The beverages
may contain milk ingredients, so participants with known milk allergies will be excluded from study
participation.
According to the American College of Sports Medicine, the risks associated with maximal
exercise/testing for healthy individuals are very minimal. Any subjects who do not meet the
criteria for “low risk” will not be allowed to participate in the study. In the unlikely event of cardiac
or other complications during exercise, an emergency plan is in place. This includes immediate
access to a phone to call emergency personnel. In addition, each of the investigators is CPR
certified.
The exercise protocol may result in minor-moderate levels of muscle soreness and fatigue for 1-2
days following each exercise session. However, the level of muscle soreness is expected to be
lower than levels normally experienced when people perform other „normal‟ activities that are not
part of their regular exercise routine (i.e. if a cyclist played a game of basketball with friends for 2
hours).
The risks of blood draws include possible mild bruising, and the risk of transfer of blood-borne
pathogens. This risk is considered to be very minimal, and all safety precautions for handing
blood samples will be followed according to OSHA protocols. The investigators have been
trained in phlebotomy and completed JMU blood-borne pathogen training. The total amount of
blood removed in these trials is considered very minimal. Approximately 60-70 ml of blood
collected during the entire study, which is considered very minimal. For reference, this is less
than 1/5 of a can of soda, or 15% of the amount given when donating blood in a single session
(approximately 1 pint, or 473 ml).
Benefits:
Benefits include free maximal oxygen uptake testing, use of cutting-edge nutrition products, and a
$200 stipend for study completion. In the event that I am unable to complete all testing,
payments will be distributed in the following manner: $25 for completing the familiarization trial,
$25 for completing experimental trial 1, and $50 for completing experimental trial 2.
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Inquiries:
If you have any questions of concerns, please contact Dr. Michael Saunders at
saundemj@jmu.edu or (540) 568-8121. In the case of any immediate concerns or adverse
reactions during the study, contact Dr. Saunders at his cell phone (540) 560-3032.
Confidentiality:
All data and results will be kept confidential. Subjects will be assigned an identification code. At
no time will a subject‟s name be identified with individual data. The researcher retains the right to
use and publish non-identifiable data. All data will be kept secured in a locked cabinet. Upon
completion of the study, all information that matches up individual respondents with their answers
will be destroyed. Final aggregate results will be made available to participants upon request.
Freedom of Consent
Your participation is entirely voluntary. You are free to choose not to participate. Should you
choose to participate, you can withdraw at any time without consequences of any kind.
I have read this consent form and I understand what is being requested of me as a participant in
this study. I freely consent to participate. I have been given satisfactory answers to my
questions. The investigator provided me with a copy of this form. I certify that I am at least 18
years of age.
Name of Subject (Printed)

Name of Researcher (Printed)

Name of Subject (Signed)

Name of Researcher (Signed)

Date

Date

For questions about your rights as a research subject, you may contact the chair of JMU’s
Institutional Review Board (IRB). Dr. David Cockley, (540) 568-2834, cocklede@jmu.edu.
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Appendix II
AHA/ACSM Health/Fitness Facility Pre-participation Screening Questionnaire
Assess your health status by marking all true statements
History
You have had:
a heart attack
heart surgery
cardiac catheterization
coronary angioplasty (PTCA)
pacemaker/implantable cardiac
defibrillator/rhythm disturbance
heart valve disease
heart failure
heart transplantation
congenital heart disease

If you marked any of these statements
in this section, consult your physician
or other appropriate health care
provider before engaging in exercise.
You may need to use a facility with a
medically qualified staff.

Symptoms
You experience chest discomfort with exertion
You experience unreasonable breathlessness
You experience dizziness, fainting, or blackouts
You take heart medications
Other Health Issues
You have diabetes
You have asthma or other lung disease
You have burning or cramping sensation in your lower
legs when walking short distances
You have musculoskeletal problems that limit your
physical activity
You have concerns about the safety of exercise
You take prescription medication(s)

Cardiovascular risk factors
You are a man older than 45 years
You are a woman older than 55 years, have had a
hysterectomy, or are postmenopausal
You smoke, or quit smoking within the previous 6 months
Your blood pressure is > 140/90 mmHg
You do not know your blood pressure
You take blood pressure medication
Your blood cholesterol level is > 200 mg/dl
You do not know your cholesterol level
You have a close blood relative who had a heart attack or
heart surgery before age 55 (father or brother) or age 65
(mother or sister)
You are physically inactive (i.e. you get < 30 minutes of
physical activity on at least 3 days of the week)
You are > 20 pounds overweight

None of the above

If you marked two or more of
the statements in this section,
you should consult your
physician or other appropriate
health care provider before
engaging in exercise. You
might benefit from using a
facility with a professionally
qualified exercise staff to guide
your exercise program.

You should be able to exercise safely
without consulting your physician or
other appropriate health care provider
in a self-guided program or almost
any facility that meets your exercise
program needs.
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Appendix III
Borg Rating of Perceived Exertion Scale (6 - 20)
Exertion

RPE

no exertion at all

6

extremely light

7
8

very light

9
10

light

11
12

somewhat hard

13
14

hard (heavy)

15
16

very hard

17
18

extremely hard

19

maximal exertion

20
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Appendix IV
Muscle Soreness Questionnaire
Subject #

Trial #

Circle: Pre

4-Post

24-Post

Date:

Muscle Soreness
Please place a mark on the line below corresponding to your level of muscle soreness
0 millimeters (left) = complete absence of muscular soreness
100 millimeters (right) = extremely sore with noticeable pain and stiffness at all times

0 mm

Score:

100 mm

mm (to be completed by researcher)
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